

1 **SARS-CoV-2 viral replication persists in the human lung for several weeks after symptom**
2 **onset**

3

4 **Running title:** Persistence of SARS-CoV-2 in the human lung.

5

6 Tomasicchio M^{1,2}, Jaumdally S^{1,2}, Wilson L^{1,2}, Kotze A^{1,2}, Semple L^{1,2}, Meier S^{1,2}, Pooran A^{1,2},
7 Esmail A^{1,2}, Pillay K⁵, Roberts R⁵, Kriel R⁵, Meldau R^{1,2}, Oelofse S^{1,2}, Mandviwala C^{1,2}, Burns
8 J^{1,2}, Londt R^{1,2}, Davids M^{1,2}, van der Merwe^{1,2} C, Roomaney A^{1,2}, Kühn L^{1,2}, Perumal T^{1,2},
9 Scott A.J^{1,2}, Hale M.J⁶, Baillie V⁷, Mahtab S⁷, Williamson C⁸, Joseph R⁸, Sigal A⁹, Joubert I¹⁰,
10 Piercy J¹⁰, Thomson D¹⁰, Fredericks DL¹⁰, Miller MGA¹⁰, Nunes M.C⁷, Madhi S.A⁷, Dheda
11 K^{1,2,3,4}.

12

13 **Affiliations:**

14 ¹ Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine,
15 University of Cape Town and UCT Lung Institute, FCape Town, South Africa.

16 ² South African MRC Centre for the Study of Antimicrobial Resistance, University of Cape
17 Town, Cape Town, South Africa.

18 ³ Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape
19 Town, South Africa.

20 ⁴ Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection,
21 London School of Hygiene & Tropical Medicine, London, UK.

22 ⁵ Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape
23 Town, South Africa

24 ⁶ Division of Anatomical Pathology, Faculty of Health Sciences, University of the
25 Witwatersrand.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 ⁷ South African Medical Research Council, Vaccines and Infectious Diseases Analytics
27 Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,
28 South Africa; Department of Science and Technology/National Research Foundation South
29 African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences,
30 University of the Witwatersrand, Johannesburg, South Africa.

31 ⁸ Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine,
32 University of Cape Town, Cape Town, South Africa.

33 ⁹ Africa Health Research Institute, Durban, South Africa.

34 ¹⁰ Division of Critical Care, Department of Anaesthesia and Perioperative Medicine, University
35 of Cape Town, South Africa.

36

37 Correspondence: Keertan Dheda, Centre for Lung Infection and Immunity, Division of
38 Pulmonology and UCT Lung Institute, Dept of Medicine, University of Cape Town, South
39 Africa. E-mail: keertan.dheda@uct.ac.za

40

41

42 **ABSTRACT**

43 **Rationale:** In the upper respiratory tract replicating (culturable) SARS-CoV-2 is recoverable
44 for ~ 4 to 8 days after symptom onset, however, there is paucity of data about the frequency or
45 duration of replicating virus in the lower respiratory tract (i.e. the human lung).

46 **Objectives:** We undertook lung tissue sampling (needle biopsy), shortly after death, in 42
47 mechanically ventilated decedents during the Beta and Delta waves. An independent group of
48 18 ambulatory patents served as a control group.

49 **Methods:** Lung biopsy cores from decedents underwent viral culture, histopathological
50 analysis, electron microscopy, transcriptomic profiling and immunohistochemistry.

51 **Results:** 38% (16/42) of mechanically ventilated decedents had culturable virus in the lung for
52 a median of 15 days (persisting for up to 4 weeks) after symptom onset. Lung viral culture
53 positivity was not associated with comorbidities or steroid use. Delta but not Beta variant lung
54 culture positivity was associated with accelerated death and secondary bacterial infection
55 ($p < 0.05$). Nasopharyngeal culture was negative in 23.1% (6/26) of decedents despite lung
56 culture positivity. This, hitherto, undescribed bio-phenotype of lung-specific persisting viral
57 replication was associated with an enhanced transcriptomic pulmonary pro-inflammatory
58 response but with concurrent viral culture positivity.

59 **Conclusions:** Concurrent, rather than sequential active viral replication continues to drive a
60 heightened pro-inflammatory response in the human lung beyond the second week of illness
61 and was associated with variant-specific increased mortality and morbidity. These findings
62 have potential implications for the design of interventional strategies and clinical management
63 of patients with severe COVID-19 disease.

64 243 words

65 **Keywords:** COVID-19, SARS-CoV-2, virus replication, mechanically ventilated patients,
66 upper respiratory tract, immunology

67 **At a Glance Commentary**

68 **Scientific Knowledge on the Subject:**

69 Investigations to understand SARS-CoV-2 viral shedding (determined by PCR or antigen
70 testing) have extensively focused on samples from the upper respiratory tract. The widely
71 accepted view is that acute severe SARS-CoV-2 infection is characterised by a viral replicative
72 phase in the first week of symptomatic illness followed by a pro-inflammatory
73 immunopathologic phase peaking in the second and third weeks of illness. However, it remains
74 unclear whether detection of SARS-CoV-2 beyond 2 weeks after symptom onset in published
75 studies represent active replication competent virus because it may represent residual genomic
76 or antigenic material in the tissue.

77

78 **What This Study Adds to the Field:**

79 We have identified a, hitherto, undescribed bio-phenotype of acute severe COVID-19
80 characterised by persisting viral replication in the lung for up to 4 weeks after symptom
81 onset. ~40% of acute severe COVID-19 intensive care unit (ICU) decedents (n=42) had
82 nasopharyngeal swab culture positivity at ~2 weeks post-symptom onset versus only ~5% in a
83 group of ambulatory control patients (n=18). There was compartment-specific (nasopharynx
84 versus lung) discordance. The phenotype of lung-specific persisting viral replication was
85 associated with variant-specific accelerated death, an exaggerated inflammatory response, and
86 attenuated T-cell immunity in the lung (based on histopathological and transcriptomic studies).
87 This challenges the traditional view that viral replication occurs during the first 5 to 10 days of
88 illness, which is followed by an effector or hyperinflammatory phase. This is the first study, to
89 our knowledge, to systematically culture virus from the human lung and map out its related
90 clinical determinants, and which describes the human lung transcriptomic profile of culture-
91 positive versus culture-negative patients with severe COVID-19 disease.

92 **Introduction.**

93 Coronavirus disease-19 (COVID-19) caused by the Severe Acute Respiratory Syndrome
94 Coronavirus-2 (SARS-CoV-2) has been the foremost killer globally over the last 3 years. Case
95 fatality risk in hospitalised patients, and particularly in mechanically ventilated patients, during
96 the Beta and Delta waves was particularly high [\sim 50%-70%; (1)]. Even with the Omicron-
97 related variants, case fatality risk remains significant in the elderly and immunocompromised
98 persons, and in several countries including the UK, Italy, France, Brazil, and prominently in
99 China where there is now an ongoing epidemic of severe COVID-19 disease (2-10). Better
100 therapeutic interventions are needed. However, despite considerable research, the pathogenesis
101 of severe COVID-19, relative to viral kinetics, remains incompletely understood.

102

103 SARS-CoV-2 detection (ascertained through PCR positivity or antigen detection) can persist
104 for several weeks from symptom onset (11). Post-mortem studies have shown persistence of
105 SARS-CoV-2 in tissues detected by PCR and immunohistochemistry for up to several weeks
106 after symptom onset (12, 13). However, detection of SARS-CoV-2 in these studies may not
107 represent replication competent virus (detectable only by viral culture) but residual genomic or
108 antigenic material in the tissues. Shedding of replicating virus confirmed through serial viral
109 culture (i.e. *in vitro* replication in human cell lines) from the upper respiratory tract (URT) has
110 been shown to persist for only \sim 2 to 8 days after symptom onset (11, 14-23). These findings
111 have been confirmed in human lung challenge studies with viable pathogen where virus was
112 cultured from the URT until a median of 4 days (and a maximum of 10 days) from symptom
113 onset (24). However, hardly anything is known about the compartment-specific duration of
114 actively replicating virus in the lower respiratory tract (LRT), particularly in acute severely ill
115 hospitalised patients undergoing mechanical ventilation. We hypothesised that there is
116 compartment-specific uncoupling of viral replication in severe COVID-19 i.e. replicating virus

117 can persist in the LRT beyond 10 days from symptoms onset, independent of its persistence in
118 the URT, and this persistence may be associated with an altered pulmonary immunity.

119

120 **Methods.**

121 **Patients.**

122 The decedents (n=42) were recruited from Chris Hani Baragwanath Academic Hospital,
123 Johannesburg, South Africa (n=18; Beta group) and Groote Schuur Hospital, Cape Town, South
124 Africa (n=24; Delta group). Figure 1A outlines an overview of the study plan. Ambulatory
125 controls (n=18) were recruited at diagnosis (baseline; ~5 days from symptom onset), 7 days and
126 14 days post diagnosis. Minimally invasive tissue samples (MITS) and nasopharyngeal swabs
127 from decedents (n=42) in the Beta and Delta waves (Figure 1B) were taken immediately after
128 death. In addition, heart, liver, kidney, and adipose tissue samples were also taken from the
129 Delta variant decedent cohort only. Ethical approval was obtained from the Human Research
130 Ethics Committee (HREC) of the University of Cape Town (HREC approval number 866/2020)
131 and University of Witwatersrand (HREC approval number M200313). Biosafety approvals
132 were obtained from the Faculty Biosafety Committee of the University of Cape Town (IBC008-
133 2021).

134

135 **Viral culture.**

136 To establish the *in vitro* viral culture model, a SARS-CoV-2 viral stock was used to infect the
137 human lung carcinoma cell line, H1299 ACE2, in a BSL3 laboratory and infection was
138 confirmed by light microscopy (as assessed by cytopathic effects of the virus on the cell line)
139 and confocal microscopy (Figure S1A and B). Serial dilutions of the viral stock were used to
140 establish the limit of detection of the PCR assay at 1×10^1 copies/ml (Figure S1C). Viral culture
141 was performed on the nasopharyngeal swab and lung biopsy samples as indicated in the study

142 overview (Figure 1) and detailed in the online supplement. Viral culture result reproducibility
143 was good (see online supplement).

144

145 **Multiplex PCR to detect secondary bacterial infections.**

146 The lung biopsy cores, stored in universal transport medium, were briefly homogenised and
147 200µl of the supernatant was applied to the BioFire FilmArray Pneumonia panel (Biomérieux,
148 South Africa). The panel was run using protocol BAL v3.3 according to the manufacturer's
149 instructions, thus generating RT-PCR readouts for 33 bacterial and viral pathogens.
150 Bronchopneumonia was defined as histological evidence of a neutrophilic alveolar infiltration
151 together with the detection of bacterial genomic material in the biopsy cores.

152

153 **Immunohistochemistry.**

154 Immunohistochemical staining was performed using the Roche Ventana Automated platform
155 (Ventana XT autostainer) as indicated by the manufacturer. Tissue sections were prepared,
156 stained, and viewed using standard techniques (25). Antibodies included anti-CD3 (2GV6),
157 and anti-CD8 (SP57) (Roche USA).

158

159 **Haematoxylin & eosin (H&E) staining and transmission electron microscopy (TEM).**

160 H&E staining and TEM were performed according to standard procedures (25). H&E-stained
161 slides were viewed using an Olympus BX43 microscope. TEM tissue sections were viewed
162 using a Carl Zeiss EM109 microscope.

163

164 **SARS-CoV-2 whole genome sequencing.**

165 Total SARS-CoV-2 RNA was extracted from lung biopsy samples and whole genome
166 sequencing was performed. The generated reads were analysed with the Exatype

167 (<https://exatype.com>) software to identify minor and major variants. The assembled consensus
168 sequences were analysed using Nextclade Web (<https://clades.nextstrain.org>) for further quality
169 control and clade assignment.

170

171 **RNAseq.**

172 Total RNA was extracted from lung biopsy samples from the Delta group, sequenced and
173 mapped consecutively to the human and COVID reference genomes using the Spliced
174 Transcripts Alignment to a Reference (STAR) software [version 2.7.7a, (26)]. A differential
175 expression (DE) analysis was performed on the generated raw read count file with the edgeR
176 (Version 3.38.4) R package (27). The DE results were ranked by fold change and the gseGO
177 function, from the clusterProfiler R clusterProfiler [Version 4.0, (28)] R package was used to
178 perform a gene set enrichment analysis (GSEA) for the Gene Ontology Biological Process
179 pathways. Pathways with an FDR <0.05 were considered significant.

180

181 **Confocal microscopy.**

182 The H1299 ACE2 cells were plated, infected with SARS-CoV-2 and allowed to adhere to
183 coverslips slides overnight at 37°C. The next day the cells were stained with or without anti-
184 SARS-CoV-2 S1 spike protein (ThermoFisher, USA) and the slides were mounted in Mowiol
185 (Calbiochem, USA) containing n-propyl gallate (Sigma-Aldrich, Germany) as an anti-fading
186 agent. Confocal microscopy was performed with a Zeiss Axiovert 200M LSM510 Meta NLO
187 Confocal Microscope.

188

189 **Sample size calculation and statistical analysis.**

190 We hypothesised that we would detect lung culture positivity at 14 days post-symptom onset
191 in ~33% of decedents. A sample size of ~40 participants would allow us to ascertain that level

192 of positivity with a 15% margin of error using 95% confidence and 80% power (OpenEpi,
193 Version 3, opensource calculator).

194
195 The Fisher Exact test was employed for categorical variables and for continuous variables,
196 Mann-Whitney test was used for non-parametrically distributed data between the culture-
197 negative and culture-positive groups (Stata version 17 or GraphPad, Version 9.4.1). A p-value
198 of < 0.05 was considered significant for all statistical analyses.

199
200 The multivariable analysis was performed in R by fitting a binomial Generalized Linear Model
201 (GLM) to assess the association between steroid use and the presence of secondary bacterial
202 infection on culture status. The tidymodels (version, 1.0.0) R package was used to perform
203 predictive modelling using the glm binomial classification algorithm. To account for the small
204 sample size, 1000 bootstraps were performed for each analysis using the “bootstraps” function
205 (non-parametric) from the rsample package (version 1.2.0).

206

207 **Results**

208 **Demographics and clinical characteristics of the decedents.**

209 The demographics of patients enrolled in the study are shown in Table S1. The median age of
210 the patients was 53 years with 48% being males (20/42). 40.5% (17/42) had a secondary
211 bacterial infection and 11% (4/38) had bacterial bronchopneumonia (microbiologically and
212 histopathological confirmed). The median time from onset of symptoms to death, ICU
213 admission to death and high flow oxygen admission to death was 17 (IQR; 9-22), 5 (2-12) and
214 11 (6-15) days, respectively.

215

216 **SARS-CoV-2 replicating persistence in the human lung of mechanically ventilated**
217 **decedents.**

218 We first ascertained the frequency and duration of replicating virus in lung tissue (which to our
219 knowledge has not been previously undertaken). Culturable virus in the lung was present in
220 38.1% (16/42; Figure 2A) of mechanically ventilated ICU decedents, at a median of 15 days
221 (and up ~4 weeks; Figure S2) from symptom onset to sampling/death (Figure 3A). As expected,
222 56% (10/18) of a prospectively recruited control group of ambulatory patients had culturable
223 virus, using nasopharyngeal swab samples, at day 5 from symptom onset (Figure 2B). In the
224 same group of patients after 12- and 19- days after symptom onset, only 5.5% (1/18) and 0%
225 (0/18), respectively, had culturable virus from their nasopharyngeal swab (Figure 2B). By
226 contrast, 38% of nasopharyngeal swabs from the mechanically ventilated ICU descendants had
227 culturable virus (Figure 2B), at a median of 13 days from symptom onset to sampling/death
228 (Figure S3B). Additionally, SARS-CoV-2 could be detected by PCR in multiple organs in lung
229 culture-positive decedents in the Delta cohort (biopsies other than the lung was not performed
230 in the Beta cohort) suggesting widespread multi-organ viral dissemination (Figure 2C). SARS-
231 CoV-2 was also detected in adipose tissue of culture-positive decedents (hitherto undescribed).
232 We did not culture virus from the organs of the decedents other than the lung. Thus, viral genetic
233 material was only detectable by PCR in the lung culture-positive patients in the other organs.
234 This probably indicates that the virus disseminated systemically in these patients, who had
235 chronic replicative disease in the lung and not in the other organs. We therefore only presented
236 the PCR results from the other organs for the lung-culture positive patient samples in Figure
237 2C. Clinical characteristics, such as, age and comorbidities were similar in the lung culture-
238 positive versus culture-negative groups (Table S1). We found no association between viral
239 genetic variant and the phenotype of replicating viral persistence (although this might have been
240 a factor of the limited sample size; Table S5).

241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264

Time to death in the Delta and Beta groups and predictors of lung culture positivity.

Next, we evaluated variant-specific relationships to clinical outcomes. Mechanically ventilated patients who were SARS-CoV-2 lung culture-positive in the Delta, but not the Beta group, had a higher proportion of accelerated death (i.e. shorter duration from symptom onset to death; Figure 3C versus 3B; $p=0.004$), and a higher proportion of lung-specific secondary bacterial infection (Figure 3F versus 3E; $p=0.032$) compared to culture-negative decedents. Similarly, to the lung culture data, the nasopharyngeal swab culture-positive Delta, but not the Beta group, had a higher proportion of accelerated death (Figure S3D versus S3C; $p=0.026$).

The bacterial species identified from the lung biopsies of both the Beta and Delta groups included *Streptococcus*, *Staphylococcus*, *Haemophilus*, *Acinetobacter*, *Proteus* spp, *Escherichia*, *Klebsiella*, *Enterobacter* and *Serratia* (Table S4). Overall, both groups were infected with one or more bacteria that were sensitive or resistant to β -lactams and/or carbapenems (Table S4). Key clinical and demographic characteristics such as differences in co-morbidities (age, obesity, diabetes, HIV positivity etc; Table S1) associated as drivers of severe COVID-19 disease and poor prognosis, could not explain these observations, despite the lower population-level vaccination and pre-existing COVID-19 exposure rates in the Beta cohort. Steroid usage (proportion) was similar in the culture-positive and culture-negative groups (Table S1; though the duration of steroid usage was significantly higher in the culture negative group), and there was no significant ($p>0.05$) association between steroid use and lung culture positivity or the presence of secondary bacterial infection in a multivariable analysis. If anything, there was a trend ($p=0.06$) to greater steroid exposure in the lung culture negative group (in the multivariable analysis) arguing against its role in driving viral replication.

265 Next, we interrogated whether nasopharyngeal PCR characteristics (Ct value), either at
266 admission or close to death, could identify the phenotype of lung replicating viral persistence.
267 However, nasopharyngeal Ct neither at admission, nor at the time of death was associated with
268 lung culture positivity (Figure 3G). This suggests that the kinetics of viral replication was
269 different in the upper and the lower respiratory tract.

270

271 **Lung immunity and histology of the culture-negative versus culture-positive groups.**

272 We then ascertained whether the phenotype of replicating viral persistence was associated with
273 attenuated or modulated lung immunity in the Delta decedents (transcriptomic and flow
274 cytometric studies were only carried out in Cape Town, i.e the Delta decedents, due to location-
275 specific availability of assays and limited Beta group biopsy cores that had been used for
276 unrelated studies). Immunohistochemical staining indicated that there was significantly less
277 infiltration of CD3+ T-cells, specifically CD8+ T-cells in the alveoli and interstitium of the
278 SARS-CoV-2 culture-positive compared with the culture-negative individuals in the Delta
279 decedents (Figure 4A and B).

280

281 The typical histological features of severe COVID-19 (e.g. diffuse alveolar damage and
282 microvascular thrombosis) were similar in the SARS-CoV-2 culture-positive and the culture-
283 negative phenotype suggesting that these events occurred in the early rather than the persistent
284 viral replication phase (Figure 4C, D and S4; Table S2, S3). Interestingly, we observed that
285 some features of leukocyte hyperactivation (i.e., hemophagocytic syndrome) were more
286 common in the SARS-CoV-2 culture-negative versus the culture-positive group, potentially in
287 keeping with an aberrant immune response characterised by a lack of immune regulation, as
288 outlined above (Figure 4C and 4D; $p=0.013$).

289 The transcriptional analysis of post-mortem lung tissue after adjustment for multiple testing,
290 identified a total of 11 up- and 4 down-regulated genes in the culture-positive versus culture-
291 negative groups (FDR<0.05; specific genes discussed further in the online supplement; Figure
292 S6). To ensure that the transcriptional signal was uniform, lung biopsy cores from each decedent
293 were placed in 1 tube containing RNAlater to ensure that enough genetic material was obtained.
294 The lung-culture-positive group expressed higher levels of carbonic anhydrase 12 (CA12) than
295 the lung culture-negative group (Figure S6 and Table S6). This protein induces a phenotype
296 similar to high-altitude pulmonary oedema with a decreased ratio of arterial oxygen, partial
297 pressure to fractional inspired oxygen, and a reduction of the carbon dioxide levels (29). This
298 was associated with increased tachypnoea and fibrinogen levels/fibrin formation and the
299 presence of hypoxia leading to acute respiratory distress syndrome [ARDS; (29)].

300 Another gene that was highly overexpressed in the culture-positive cohort was CD177, a
301 glycosylphosphatidylinositol (GPI)-anchored protein expressed by neutrophils. CD177 plays a
302 key role in neutrophil activation, transmigration and adhesion to the endothelium and is
303 associated with the severity of COVID-19 disease (Figure 6, S6 and Table S6) (30). Fu et al
304 (31) reported a high neutrophil to lymphocyte ratio in the alveolar spaces of the lung from
305 deceased patients with COVID-19. Elevated levels of CD177 were recently identified by
306 transcriptomics in the peripheral blood (32) and by proteomics in bronchoalveolar lavage cells
307 (33) of COVID-19 patients with mild and severe disease, which supports our data of an
308 upregulation of CD177 in the lung culture-positive decedents.

309
310 Syndecan binding protein 2 was significantly upregulated in the culture-positive versus the
311 culture-negative group (Figure S6 and Table S6). The protein is a family member of the
312 syndecans (SDC) which are transmembrane proteoglycans that facilitate the cellular entry of
313 SARS-CoV-2 (34). Endothelial cells express SDC2 and during virus internalization and

314 syndecans colocalize with ACE2, suggesting a jointly shared internalization pathway. Hudak
315 et al (34) reported that entry via SDCs enabled efficient gene transduction with SARS-CoV-2
316 pseudovirus which implied that SDC-mediated internalisation pathway maintained the viral
317 particles biological activity. Viruses that target SDCs in the lung may therefore interfere with
318 SDC-dependent signalling as inhibitors to both ACE2 and syndecan reduced the cellular entry
319 of SARS-CoV-2, thus supporting the complex nature of internalization.

320

321 The GSEA performed using the full list of differentially expressed genes ranked by fold-change,
322 identified activated pathways that were associated with a proinflammatory response related to
323 cytokine signalling, neutrophil and monocyte chemotaxis/recruitment, and viral entry/defence,
324 all of which are implicated in COVID-19-related hypercytokinaemia (35) (Figure 5, 6, S5, S6,
325 Table S6 and S7A). Significantly repressed pathways were generally associated with body
326 homeostasis (Figure 5A and B). There was also in tandem upregulation of Th1 and Th17
327 signalling pathways (Table S7B) but to a substantially lesser extent than that of innate cellular
328 and signalling pathways (IL-1, IL-6 and neutrophil-related; Table S7A). These features may be
329 consistent with an aberrant immune response including a lack of activation of regulatory and
330 immune-suppressive pathways. T-cell exhaustion consistent with upregulation of PD-1, CTLA-
331 4 and LAG (Table S7C) known to be associated with severe COVID-19, was not observed.

332

333 The differential expression (DE) results also revealed that a number of SARS-CoV-2 genes
334 were significantly upregulated (FDR<0.01) in the culture-positive versus the culture-negative
335 group including *nucleocapsid phosphoprotein* (log₂ FC=8.4) and *ORF3a* (log₂ FC=5.5) while
336 the *surface/spike glycoprotein* encoding gene had a log₂ FC of 5.3 and an FDR of 0.067 (Table
337 S6). A visual inspection of the mapped SARS-CoV-2 reads revealed that those that mapped to
338 the 5' end of the genes were spliced with a portion mapping to the 5' leader sequence of the

339 genome. This suggests the reads originated from sub-genomic mRNA (sgRNA) rather than
340 genomic RNA which is consistent with the active viral replication observed in the culture-
341 positive group.

342
343 Finally, we evaluated whether any of the DE genes could act as biomarkers discriminating
344 between lung culture-positive and negative-individuals. Logistic regression predictive
345 modelling revealed that *GREM1* and *FGFBP1* were associated with a sensitivity and specificity
346 above 90% (Figure S6). Future studies are warranted to determine if these lung-based
347 biomarkers can predict patient culture status in blood samples.

348
349 **Discussion.**

350 The widely accepted view in severe acute COVID-19 is that resolution of the initial viral
351 replication phase in the first week after symptom onset is followed by an effector or
352 hyperinflammatory phase in the second and third week of illness, which is characterised by
353 diffuse alveolar damage, thrombo-inflammation, and endotheliopathy (36). Indeed, the
354 Infectious Disease Society of America (IDSA) recommends the use of remdesivir for only 5
355 days in patients with severe illness and not at all in mechanically ventilated patients (37).
356 However, our results, based on post-mortem lung biopsies obtained using minimally invasive
357 tissue sampling methods (MITS) shortly after death indicated that, in contradistinction to the
358 URT where replication often ceases within ~8 days from symptom onset, in the human lung
359 virus is culturable in ~40% of mechanically ventilated patients until death (median of 15 days
360 and up to 4 weeks after symptom onset; see Figure 1 for the study overview). To ensure
361 reproducibility of the lung biopsy procedure, histological analysis was performed to confirm
362 that the tissue was derived from the lung only (to ensure that there was no contamination from
363 other tissue or muscle, which would have been detected on histopathological analysis at the

364 least to some extent). The upregulation of muscle-associated gene pathways may have been
365 related to virus-associated myositis or ICU-associated myopathy. The culture-positive group in
366 the Delta cohort had accelerated death and a higher proportion of secondary bacterial infection
367 in the lung compared to the culture-negative group. This may be explained by the Delta variant
368 being more transmissible (38), associated with enhanced replication, higher viral load (39) and
369 greater immune escape (40) than the Beta variant.

370 Nasopharyngeal SARS-CoV-2 viral load (based on Ct value) neither at admission nor at death,
371 was predictive of lung culture-positivity. SARS-CoV-2 culture-positivity in the lung of
372 decedents was associated with attenuated pulmonary T-cell immunity and an exaggerated pro-
373 inflammatory phenotype. Importantly, this was concurrent with, rather than sequential to the
374 viral replication or viral culture-positive phase.

375
376 These findings challenge the traditional paradigm of an initial viral replicative phase in the first
377 week of severe illness sequentially followed by an effector or inflammatory phase (36). Our
378 data suggest that in ~40% of ventilated patients, viral replication persisted until death (i.e. 3rd
379 and 4th week of illness and a median of 15 days after symptom onset) compared to ~2 to ~8
380 days in the URT as outlined in several studies including a live virus human challenge study (11,
381 14-24). One outlier study reported culturing virus from the URT for up to 3 weeks after
382 symptom onset (41). However, a large proportion of patients were immunocompromised,
383 samples at diagnosis and follow-up were combined (skewing the results), a high proportion of
384 participants were healthcare workers (re-infection may have been a confounder), and as the
385 authors suggested a limitation was that the Vero cell line used was overtly permissive to
386 infection compared to the human lung carcinoma cell line, H1299 ACE2, which is a biologically
387 representative cell line (and one that we used). Another recent study showed that infectious
388 virus production peaked in the human lung within 2 days, but this model used *ex vivo* agarose

389 infused devascularised and explanted human lung slices, which are not representative of what
390 is occurring in freshly harvested human lung (42). The culture-based findings in the afore-
391 mentioned studies must be explicitly distinguished from studies that detected residual free viral
392 genomic RNA (but not replicating virus) embedded in the respiratory tract tissue of patients
393 that had severe disease for an extended period of time (13, 43, 44). Indeed, SARS-CoV-2 RNAs
394 have been detected in patient tissue many months after recovery from acute infection (45-47).
395 It was initially suggested that sgRNA (sub-genomic RNA; small strands of reversely
396 transcribed RNA) could be used as a proxy to infer viral replication. However, several recent
397 studies have indicated that it has poor predictive value as a proxy for viral replication (48, 49).
398 Indeed, Stein et al (13) detected sgRNA in multiple post-mortem organ biopsies, including the
399 brain, several months after symptom onset. Thus, the data presented in this manuscript is the
400 first to do so conclusively and comprehensively using viral culture from lung tissue (the gold
401 standard to detect viral replication) beyond two weeks after symptom onset.

402

403 We demonstrated active viral replication in the lungs of acutely ill ventilated patients for up to
404 ~4 weeks after symptom onset. This challenges the current practice of using antivirals like
405 remdesivir for only 5 days and suggests that a longer duration of treatment may be required in
406 critically ill patients. Furthermore, antivirals like remdesivir are not recommended for use by
407 IDSA in mechanically ventilated patients (conditional recommendation) as they felt that such
408 patients (often in the third week of their illness) are no longer in the viral replicative phase, and
409 published controlled trial data showed no mortality benefit of remdesivir in such patients (37,
410 50). However, these studies demonstrated a group effect, and the analyses did not adjust for
411 disease severity or the time from symptom onset to death in mechanically ventilated patients
412 (51). Our data suggest that a significant number of patients may likely benefit from antivirals
413 during mechanical ventilation. Indeed, several observational studies have found a survival

414 benefit using remdesivir in mechanically ventilated patients, but this requires further
415 clarification in appropriate trials (51-53). It is also possible that the very advanced
416 immunopathology in some patients may render antivirals redundant. In a multivariate analysis
417 we found no association between steroid usage and lung viral culture positivity - in fact, steroid
418 usage was lower in the viral culture-positive group (and there was a trend to an inverse
419 relationship in the multivariable analysis, and often culture positivity persisted beyond the 10
420 days of steroid usage.

421
422 The transcriptomic data suggested that, in a significant number of patients, the
423 hyperinflammatory and viral replication phase occur concurrently in the 3rd and 4th week of
424 illness, in contradistinction to the widely held view that these are sequential phases. Antiviral
425 and selective proinflammatory responses were over-represented in the SARS-CoV-2 culture-
426 positive compared with the culture-negative decedents, and we did not detect attenuated type 1
427 interferon responses at the site of disease compared with other reports (54-58). Three prior
428 studies (one that enrolled 5 COVID-19 patients) evaluated transcriptomic lung responses in
429 patients with severe COVID-19 versus healthy controls (54, 55, 59). These first level studies
430 logically attempted to address the significance of transcriptomic changes specific to COVID-
431 19 by using healthy controls or non-diseased parts of the lung from lung cancer patients.
432 However, we specifically sought to compare culture-positive versus culture-negative groups
433 (hitherto not undertaken) to dissect out pathways that facilitate permissiveness to ongoing viral
434 replication.

435
436 We identified two lung-based biomarkers (*GREM1* and *FGFBP1*) that could predict culture-
437 positivity. Although these are lung-specific biomarkers, this preliminary analysis in a limited
438 number of samples suggests that in the future, RT-PCR of tracheal aspirates or blood (if they

439 are concordant with lung findings), could potentially serve as biomarkers to identify and direct
440 appropriate treatment protocols to culture-positive persons but further investigation is needed.

441

442 There are several limitations to our findings. Firstly, our findings are relevant to acute severe
443 COVID-19 ARDS/pneumonia requiring mechanical ventilation and may not be applicable to
444 milder forms of disease seen in hospitalised patients or chronic infection seen in
445 immunocompromised patients. Second, we only studied patients with the Beta and Delta
446 variants as these were the predominant variant at the time of the study. However, Omicron has
447 also been associated with severe disease in several settings including the surge of severe
448 COVID-19 unfolding in China. Third, we did not study a control group comprising severe
449 ARDS due to other causes because our express aim was to investigate the presence and duration
450 of viral replication in the LRT in severe COVID-19 disease. Fourth, the sample size limited our
451 ability to make conclusions about several aspects. However, the highly resource intensive and
452 demanding nature of the study limited our ability to recruit higher numbers of participants.
453 Fifth, it could be suggested that there may have been sampling error and variability of the viral
454 culture assay. However, the reproducibility of the viral culture technique using 6 samples across
455 2 separate runs had a low standard error, which was indicative of high reproducibility. Sixth,
456 we did not compare the culture status of the lower respiratory tract in the ambulatory controls
457 versus the decedents. This was due to ethical reasons and the potential risks of viral transmission
458 to the medical and research staff during bronchoscopic procedures. Finally, the transcriptional
459 signature and flow cytometric findings may have been affected by post-death sampling, but
460 several detailed studies have shown (60) that most protein and RNA species are preserved and
461 stable for several hours after death. Given that biopsies for the transcriptional studies were taken
462 ~2 hours after death, we feel they are broadly representative of the picture at the time of death.

463

464 In summary, our data suggests that in COVID-19 disease there is considerable heterogeneity in
465 the frequency and duration of viral replication in the upper versus the lower respiratory tract
466 (i.e. lungs) beyond the 2nd week of illness, and that in a significant proportion of seriously ill
467 patients, persisting viral replication occurs concurrently and may drive an exaggerated
468 proinflammatory response (higher than in culture-negative persons), rather than sequentially as
469 it is widely believed. These findings have potential implications for the use of antiviral therapy
470 in seriously ill patients with COVID-19 and suggest that better biomarkers are needed to
471 identify patient phenotypes and subsets that might benefit from concurrent anti-inflammatory
472 and antiviral therapy.

473 **Figure legends.**

474

475 **Figure 1. Study overview including SARS-CoV-2 PCR-positive ambulatory controls (A)**
476 **and mechanically ventilated decedents (B) recruited during the Beta and Delta waves.**

477 Nasopharyngeal (NP) swabs from ambulatory COVID-19 controls were obtained
478 approximately 5 days after symptom onset (diagnosis), and then at 12- and 19-days post
479 symptom onset. Minimally invasive tissue samples (MITS) and NP swabs were retrieved from
480 decedents shortly after death.

481

482 **Figure 2. Active replicating virus was recovered from the lungs of over one third of**
483 **decedents (16/42). (A)** Proportion of lung biopsy samples that were culture-positive from the
484 decedents. **(B)** Proportion of ambulatory patient and decedent NP swab samples that were
485 culture-positive. **(C)** PCR positivity of organs of lung culture-positive decedents from the Delta
486 cohort (organs other than the lung were not culture positive). NP= nasopharyngeal.

487

488 **Figure 3. The phenotype of replicating viral persistence, compared to the culture-negative**
489 **participants, was associated with accelerated death and a higher frequency of bacterial**
490 **bronchopneumonia in the Delta but not the Beta group. (A)** The days from symptom onset
491 to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups for both
492 groups combined, and for the Beta **(B)** and Delta **(C)** groups alone. Proportion of
493 samples/participants with a secondary bacterial infection in culture-negative and culture-
494 positive decedents overall i.e. the combined groups (Beta and Delta) **(D)**, Beta group only **(E)**,
495 and Delta group only **(F)**. **(G)** PCR cycle threshold (Ct) value at the time of death or at
496 admission could not discriminate or predict lung culture status. The nasopharyngeal swab PCR
497 Ct values at admission or death were missing for some participants because they were either

498 diagnostically confirmed by antigen testing or the Ct value was not recorded. Due to the nature
499 of the pandemic and the burden of the disease on the healthcare infrastructure at the time, Ct
500 values at peak periods were not recorded. We have conducted sensitivity and imputation
501 analyses indicating that these missing data points are redundant.

502

503 **Figure 4. A higher proportion of T-cells, macrophages and pneumonocytes infiltrate into**
504 **the lung of the culture-negative versus culture-positive decedents in the Delta group. (A)**

505 More CD3+ and CD8+ T-cells infiltrate into the alveoli and interstitial space of the lung culture-
506 negative versus culture-positive group in the Delta decedents as assessed by
507 immunohistochemistry. **(B)** Representative images (immunohistochemistry) at 200×
508 magnification showing increased T-cell infiltration into the interstitial space (**blue arrow**) in the
509 lung culture-negatives versus the culture-positives in the Delta cohort. The density of CD3+ or
510 CD8+ T-cells in the alveoli or interstitial tissue were assessed and scored as medium or high.
511 A magnitude of 10%-50% or >50% was defined as medium or high infiltration, respectively.
512 Histopathology findings **(C)** and representative images **(D)** associated with diffuse alveolar
513 damage and microvascular thrombosis in the Delta decedents. The black arrows indicate key
514 histopathological features. The magnification settings were either set at 200× or 400×. The
515 relative magnification of each light microscopy image is shown.

516

517 **Figure 5. The transcriptomic analysis revealed that the culture-positive group, in**
518 **comparison to the culture-negative group, had enrichment of activated pathways**
519 **associated with inflammation, innate immunity, responses to cytokines, and responses to**
520 **virus/ bacterial stimuli in the Delta descendants.** Dot plot illustrating the significantly
521 activated and suppressed pathways along with the gene count and ratio for each pathway **(A)**,

522 enrichment map illustrating the significantly activated and suppressed pathways along with the
523 gene count and ratio for each pathway (**B**).

524

525 **Figure 6. Transcriptomic analysis showing the association between the innate immune**
526 **response, response to virus, response to cytokine, inflammatory pathways and genes**
527 **upregulated in the culture-positive group versus the culture-negative group.** The cnetplot
528 illustrates the overlap of genes and their fold changes for selected activated pathways.
529 Significant genes ($p_{\text{adjust}} < 0.05$) that are annotated to the pathways are highlighted in red.

530

531 **Contributions**

532 K.D, MT, S.J, A.P, A.E, M.D, M.N and S.M conceived and designed experiments. K.D, A.E,
533 S.O, L.K, T.P, A.S, I.J, J.P, D.T, D.F, M.M, M.N and S.M arranged medical ethical approval,
534 recruitment of study participants and collection of study material. MT, S.J, L.W, A.K, S.M, ,
535 A.P, K.P, R.R, R.K, R.M, C.M, J.B, R.L, M.D, C vdM, A.R, M.H, V.B, S. M, C.W, and R.J
536 performed the experiments. M.T, S.J, A.P and M.D set up experimental assays. A.S provided
537 the cell line. K.D, M.T, S.J, L.W, A.K, L.S, S.M, A.P, K.P, R.R, R.L, M.H, V.B, S.M, R.J, and
538 N.M analysed and interpreted data. K.D, M.T, L.S, and S.M wrote the manuscript with input
539 from all listed authors.

540

541 **Declaration of interests**

542 The authors have no competing interests.

543

544 **Acknowledgments**

545 The authors would like to thank Arnold-Day C, Crowther M, Fernandes N, and Mitchell L from
546 the Division of Critical Care, Department of Anaesthesia and Perioperative Medicine,

547 University of Cape Town, South Africa for identifying and referring potential patients into the
548 study.

549 The study was funded by the Bill & Melinda Gates Foundation (grant number INV-017282)
550 and the South African Medical Research Council (grant number SHIP NCD 96756) with partial
551 support from the Department of Science and Technology and National Research Foundation:
552 South African Research Chair Initiative in Vaccine Preventable Diseases. The KD lab
553 acknowledges funding from the SA MRC (RFA-EMU-02-2017), EDCTP (TMA-2015SF-1043,
554 TMA-1051-TESAIII, TMA-CDF2015), UK Medical Research Council (MR/S03563X/1), NIH
555 (CRDF-OISE-16-62105) and the Wellcome Trust (MR/S027777/1). This work was co-funded
556 by The Wellcome Centre for Infectious Diseases Research in Africa is supported by core
557 funding from the Wellcome Trust (230135/Z/16/Z) and the European Union's Horizon Europe
558 Research and Innovation Actions (101046041) for genomic surveillance.

559
560 The authors would like to thank the families of the deceased who gave us permission to conduct
561 the study, which may advance our understanding of SARS-CoV-2 pathogenesis to inform future
562 clinical management of respiratory pathogen pandemics.

563

564

565

566

567

568

569

570

571

572 References.

- 573 1. Davies MA, Morden E, Rosseau P, Arendse J, Bam JL, Boloko L, Cloete K, Cohen C, Chetty N,
574 Dane P, Heekes A, Hsiao NY, Hunter M, Hussey H, Jacobs T, Jassat W, Kariem S, Kassanje
575 R, Laenen I, Roux SL, Lessells R, Mahomed H, Maughan D, Meintjes G, Mendelson M,
576 Mnguni A, Moodley M, Murie K, Naude J, Ntusi NAB, Paleker M, Parker A, Pienaar D, Preiser
577 W, Prozesky H, Raubenheimer P, Rossouw L, Schrueder N, Smith B, Smith M, Solomon W,
578 Symons G, Taljaard J, Wasserman S, Wilkinson RJ, Wolmarans M, Wolter N, Boulle A.
579 Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by
580 Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province,
581 South Africa. *Int J Infect Dis* 2022; 127: 63-68.
- 582 2. Johns Hopkins University Center for Systems Science and Engineering. Accessed on: 18 December
583 2022. Available at: <https://coronavirus.jhu.edu/map.html> 2022.
- 584 3. Cai J, Deng X, Yang J, Sun K, Liu H, Chen Z, Peng C, Chen X, Wu Q, Zou J, Sun R, Zheng W, Zhao
585 Z, Lu W, Liang Y, Zhou X, Ajelli M, Yu H. Modeling transmission of SARS-CoV-2 Omicron
586 in China. *Nat Med* 2022; 28: 1468-1475.
- 587 4. Chen X, Yan X, Sun K, Zheng N, Sun R, Zhou J, Deng X, Zhuang T, Cai J, Zhang J, Ajelli M, Yu H.
588 Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in
589 Shanghai, February-June 2022. *Emerg Microbes Infect* 2022; 11: 2800-2807.
- 590 5. Colnago M, Benvenuto GA, Casaca W, Negri RG, Fernandes EG, Cuminato JA. Risk factors
591 associated with mortality in hospitalized patients with COVID-19 during the Omicron wave in
592 Brazil. *Bioeng* 2022; 9.
- 593 6. Gautret P, Hoang VT, Jimeno MT, Lagier JC, Rossi P, Fournier PE, Colson P, Raoult D. The severity
594 of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant, in Marseille, France,
595 December 2021-February 2022. *J Med Virol* 2022; 94: 3494-3497.
- 596 7. Jassat W, Mudara C, Ozougwu L, Tempia S, Blumberg L, Davies MA, Pillay Y, Carter T, Morewane
597 R, Wolmarans M, von Gottberg A, Bhiman JN, Walaza S, Cohen C, group Da. Difference in
598 mortality among individuals admitted to hospital with COVID-19 during the first and second
599 waves in South Africa: a cohort study. *Lancet Glob* 2021; 9: e1216-e1225.
- 600 8. Maruotti A, Ciccozzi M, Jona-Lasinio G. COVID-19-induced excess mortality in Italy during the
601 Omicron wave. *IJID Reg* 2022; 4: 85-87.
- 602 9. Maslo C MA, Laubscher A, Toubkin M, Sitharam L, Feldman C, Richards GA. COVID-19: A
603 comparative study of severity of patients hospitalized during the first and the second wave in
604 South Africa. *MedRXiv* 2021.
- 605 10. Ward IL, Bermingham C, Ayoubkhani D, Gethings OJ, Pouwels KB, Yates T, Khunti K, Hippisley-
606 Cox J, Banerjee A, Walker AS, Nafilyan V. Risk of covid-19 related deaths for SARS-CoV-2
607 Omicron (B.1.1.529) compared with Delta (B.1.617.2): retrospective cohort study. *BMJ* 2022;
608 378: e070695.
- 609 11. Fontana LM, Villamagna AH, Sikka MK, McGregor JC. Understanding viral shedding of severe
610 acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature. *Infect*
611 *Control Hosp Epidemiol* 2021; 42: 659-668.
- 612 12. Ramos-Rincon JM, Herrera-Garcia C, Silva-Ortega S, Portilla-Tamarit J, Alenda C, Jaime-Sanchez
613 FA, Arenas-Jimenez J, Fornes-Riera FE, Scholz A, Escribano I, Pedrero-Castillo V, Munoz-
614 Miguelsanz C, Orts-Llinares P, Marti-Pastor A, Amo-Lozano A, Garcia-Sevila R, Ribes-
615 Mengual I, Moreno-Perez O, Concepcion-Aramendia L, Merino E, Sanchez-Martinez R,
616 Aranda I. Pathological findings associated with SARS-CoV-2 on postmortem core biopsies:
617 correlation with clinical presentation and disease course. *Front Med* 2022; 9: 874307.
- 618 13. Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, Winkler CW, Sun J, Dickey JM,
619 Ylaya K, Ko SH, Platt AP, Burbelo PD, Quezado M, Pittaluga S, Purcell M, Munster VJ,
620 Belinky F, Ramos-Benitez MJ, Boritz EA, Lach IA, Herr DL, Rabin J, Saharia KK, Madathil
621 RJ, Tabatabai A, Soherwardi S, McCurdy MT, Consortium NC-A, Peterson KE, Cohen JI, de
622 Wit E, Vannella KM, Hewitt SM, Kleiner DE, Chertow DS. SARS-CoV-2 infection and
623 persistence in the human body and brain at autopsy. *Nature* 2022; 612: 758-763.
- 624 14. Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, Kumar S, Tran T, Ko D,
625 Sivaruban T, Ngo C, Toi C, O'Sullivan MV, Sintchenko V, Chen SC, Maddocks S, Dwyer DE,



- 626 Kok J. Cell-based culture informs infectivity and safe de-isolation assessments in patients with
627 coronavirus disease 2019. *Clinical infectious diseases : an official publication of the Infectious*
628 *Diseases Society of America* 2021; 73: e2952-e2959.
- 629 15. Berengua C, Lopez M, Esteban M, Marin P, Ramos P, Cuerpo MD, Gich I, Navarro F, Miro E,
630 Rabella N. Viral culture and immunofluorescence for the detection of SARS-CoV-2 infectivity
631 in RT-PCR positive respiratory samples. *J Clin Virol* 2022; 152: 105167.
- 632 16. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A,
633 Schiffman Z, Doan K, Bastien N, Li Y, Van Caesele PG, Poliquin G. Predicting infectious
634 severe acute respiratory syndrome coronavirus 2 from diagnostic samples. *Clin Infect Dis* 2020;
635 71: 2663-2666.
- 636 17. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, Xu H. Positive RT-PCR test results in patients recovered
637 from COVID-19. *JAMA* 2020; 323: 1502-1503.
- 638 18. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Wu F, Song ZG, Huang W, Chen J, Hu BJ, Wang
639 S, Mao EQ, Zhu L, Zhang WH, Lu HZ. Persistence and clearance of viral RNA in 2019 novel
640 coronavirus disease rehabilitation patients. *Chin Med J* 2020; 133: 1039-1043.
- 641 19. Santos Bravo M, Berengua C, Marin P, Esteban M, Rodriguez C, Del Cuerpo M, Miro E, Cuesta G,
642 Mosquera M, Sanchez-Palomino S, Vila J, Rabella N, Marcos MA. Viral culture confirmed
643 SARS-CoV-2 subgenomic RNA value as a good surrogate marker of infectivity. *J Clin*
644 *Microbiol* 2022; 60: e0160921.
- 645 20. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M,
646 Gopal R. Duration of infectiousness and correlation with RT-PCR cycle threshold values in
647 cases of COVID-19, England, January to May 2020. *Euro Surveill* 2020; 25.
- 648 21. van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, van den Akker
649 JPC, Endeman H, Gommers D, Cornelissen JJ, Hoek RAS, van der Eerden MM, Hesselink DA,
650 Metselaar HJ, Verbon A, de Steenwinkel JEM, Aron GI, van Gorp ECM, van Boheemen S,
651 Voermans JC, Boucher CAB, Molenkamp R, Koopmans MPG, Geurtsvankessel C, van der Eijk
652 AA. Duration and key determinants of infectious virus shedding in hospitalized patients with
653 coronavirus disease-2019 (COVID-19). *Nat Commun* 2021; 12: 267.
- 654 22. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC,
655 Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J, Ehmann R, Zwirgmaier
656 K, Drosten C, Wendtner C. Virological assessment of hospitalized patients with COVID-2019.
657 *Nature* 2020; 581: 465-469.
- 658 23. Young BE, Ong SWX, Ng LFP, Anderson DE, Chia WN, Chia PY, Ang LW, Mak TM, Kalimuddin
659 S, Chai LYA, Pada S, Tan SY, Sun L, Parthasarathy P, Fong SW, Chan YH, Tan CW, Lee B,
660 Rotzschke O, Ding Y, Tambyah P, Low JGH, Cui L, Barkham T, Lin RTP, Leo YS, Renia L,
661 Wang LF, Lye DC, Singapore Novel Coronavirus Outbreak Research T. Viral dynamics and
662 immune correlates of coronavirus disease 2019 (COVID-19) severity. *Clin Infect Dis* 2021; 73:
663 e2932-e2942.
- 664 24. Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, Lindsell K, Hare SS,
665 Brown J, Frise R, Smith E, Hopkins C, Noulin N, Londt B, Wilkinson T, Harden S, McShane
666 H, Baillet M, Gilbert A, Jacobs M, Charman C, Mande P, Nguyen-Van-Tam JS, Semple MG,
667 Read RC, Ferguson NM, Openshaw PJ, Rapeport G, Barclay WS, Catchpole AP, Chiu C.
668 Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.
669 *Nat Med* 2022; 28: 1031-1041.
- 670 25. Suvarna SK, Layton C, Bancroft JD. Banfords theory and practice of histology techniques. *Elsevier*
671 2018.
- 672 26. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras
673 TR. STAR: ultrafast universal RNA-seq aligner. *Bioinform* 2013; 29: 15-21.
- 674 27. Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Azov AG,
675 Bennett R, Bhai J, Billis K, Boddu S, Charkhchi M, Cummins C, Da Rin Fioretto L, Davidson
676 C, Dodiya K, El Houdaigui B, Fatima R, Gall A, Garcia Giron C, Grego T, Guijarro-Clarke C,
677 Haggerty L, Hemrom A, Hourlier T, Izuogu OG, Juettemann T, Kaikala V, Kay M, Lavidas I,
678 Le T, Lemos D, Gonzalez Martinez J, Marugan JC, Maurel T, McMahon AC, Mohanan S,
679 Moore B, Muffato M, Oheh DN, Paraschas D, Parker A, Parton A, Prosovetskaia I, Sakthivel
680 MP, Salam AIA, Schmitt BM, Schuilenburg H, Sheppard D, Steed E, Szpak M, Szuba M, Taylor

- 681 K, Thormann A, Threadgold G, Walts B, Winterbottom A, Chakiachvili M, Chaubal A, De
682 Silva N, Flint B, Frankish A, Hunt SE, GR II, Langridge N, Loveland JE, Martin FJ, Mudge
683 JM, Morales J, Perry E, Ruffier M, Tate J, Thybert D, Trevanion SJ, Cunningham F, Yates AD,
684 Zerbino DR, Fliccek P. Ensembl 2021. *Nucleic Acids Res* 2021; 49: D884-D891.
- 685 28. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, Fu X, Liu S, Bo X,
686 Yu G. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *Innov* 2021;
687 2: 100141.
- 688 29. Deniz S, Uysal TK, Capasso C, Supuran CT, Ozensoy Guler O. Is carbonic anhydrase inhibition
689 useful as a complementary therapy of Covid-19 infection? *J Enzyme Inhib Med Chem* 2021; 36:
690 1230-1235.
- 691 30. Levy Y, Wiedemann A, Hejblum BP, Durand M, Lefebvre C, Surenaud M, Lacabaratz C, Perreau
692 M, Foucat E, Dechenaud M, Tisserand P, Blengio F, Hivert B, Gauthier M, Cervantes-Gonzalez
693 M, Bachelet D, Laouenan C, Bouadma L, Timsit JF, Yazdanpanah Y, Pantaleo G, Hocini H,
694 Thiebaut R, French Ccsg. CD177, a specific marker of neutrophil activation, is associated with
695 coronavirus disease 2019 severity and death. *iScience* 2021; 24: 102711.
- 696 31. Fu J, Kong J, Wang W, Wu M, Yao L, Wang Z, Jin J, Wu D, Yu X. The clinical implication of
697 dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in
698 Suzhou China. *Thromb Res* 2020; 192: 3-8.
- 699 32. Aschenbrenner AC, Mouktaroudi M, Kramer B, Oestreich M, Antonakos N, Nuesch-Germano M,
700 Gkizeli K, Bonaguro L, Reusch N, Bassler K, Saridaki M, Knoll R, Pecht T, Kapellos TS,
701 Doulou S, Kroger C, Herbert M, Holsten L, Horne A, Gemund ID, Rovina N, Agrawal S, Dahm
702 K, van Uelft M, Drews A, Lenkeit L, Bruse N, Gerretsen J, Gierlich J, Becker M, Handler K,
703 Kraut M, Theis H, Mengiste S, De Domenico E, Schulte-Schrepping J, Seep L, Raabe J,
704 Hoffmeister C, ToVinh M, Keitel V, Rieke G, Talevi V, Skowasch D, Aziz NA, Pickkers P,
705 van de Veerdonk FL, Netea MG, Schultze JL, Kox M, Breteler MMB, Nattermann J,
706 Koutsoukou A, Giamarellos-Bourboulis EJ, Ulas T, German C-OI. Disease severity-specific
707 neutrophil signatures in blood transcriptomes stratify COVID-19 patients. *Genome Med* 2021;
708 13: 7.
- 709 33. Zeng HL, Chen D, Yan J, Yang Q, Han QQ, Li SS, Cheng L. Proteomic characteristics of
710 bronchoalveolar lavage fluid in critical COVID-19 patients. *The FEBS journal* 2021; 288: 5190-
711 5200.
- 712 34. Hudak A, Letoha A, Szilak L, Letoha T. Contribution of Syndecans to the Cellular Entry of SARS-
713 CoV-2. *Int J Mol Sci* 2021; 22.
- 714 35. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we
715 know so far. *Front Immunol* 2020; 11: 1446.
- 716 36. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19.
717 *Science* 2022; 375: 1122-1127.
- 718 37. Bhimraj A MR, Shumaker AH, Baden L, Cheng VC, Edwards KM, Gallagher JC, Gandhi RT,
719 Muller WJ, Nakamura MM, O'Horo JC, Shafer RW, Shoham S, Murad MH, Mustafa RA,
720 Sultan S, Falck-Ytte Y. IDSA Guidelines on the Treatment and Management of Patients with
721 COVID-19. Accessed on: 18 December 2022. Available at: [https://www.idsociety.org/practice-](https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#Recommendations15-17:Remdesivir)
722 [guideline/covid-19-guideline-treatment-and-management/#Recommendations15-](https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#Recommendations15-17:Remdesivir)
723 [17:Remdesivir](https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#Recommendations15-17:Remdesivir). 2022.
- 724 38. Chavda VP, Apostolopoulos V. Global impact of delta plus variant and vaccination. *Expert Rev*
725 *Vaccines* 2022; 21: 597-600.
- 726 39. Liu Y, Rocklov J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher
727 compared to the ancestral SARS-CoV-2 virus. *J Travel Med* 2021; 28.
- 728 40. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira I, Datir R, Collier DA, Albecka A,
729 Singh S, Pandey R, Brown J, Zhou J, Goonawardane N, Mishra S, Whittaker C, Mellan T,
730 Marwal R, Datta M, Sengupta S, Ponnusamy K, Radhakrishnan VS, Abdullahi A, Charles O,
731 Chattopadhyay P, Devi P, Caputo D, Peacock T, Wattal C, Goel N, Satwik A, Vaishya R,
732 Agarwal M, Indian S-C-GC, Genotype to Phenotype Japan C, Collaboration C-NBC-,
733 Mavousian A, Lee JH, Bassi J, Silacci-Fegni C, Saliba C, Pinto D, Irie T, Yoshida I, Hamilton
734 WL, Sato K, Bhatt S, Flaxman S, James LC, Corti D, Piccoli L, Barclay WS, Rakshit P, Agrawal

- 735 A, Gupta RK. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature*
736 2021; 599: 114-119.
- 737 41. Folgueira MD, Luczkowiak J, Lasala F, Perez-Rivilla A, Delgado R. Prolonged SARS-CoV-2 cell
738 culture replication in respiratory samples from patients with severe COVID-19. *Clin Microbiol*
739 *Infect* 2021; 27: 886-891.
- 740 42. Pechous RD, Malaviarachchi PA, Banerjee SK, Byrum SD, Alkam DH, Ghaffarieh A, Kurten RC,
741 Kennedy JL, Xuming Z. An ex vivo human precision-cut lung slice platform provides insight
742 into SARS2 CoV-2 pathogenesis and antiviral drug efficacy. *bioRxiv* 2023.
- 743 43. Xu Q, Milanez-Almeida P, Martins AJ, Radtke AJ, Hoehn KB, Oguz C, Chen J, Liu C, Tang J,
744 Grubbs G, Stein S, Ramelli S, Kabat J, Behzadpour H, Karkanitsa M, Spathies J, Kalish H,
745 Kardava L, Kirby M, Cheung F, Preite S, Duncker PC, Kitakule MM, Romero N, Preciado D,
746 Gitman L, Koroleva G, Smith G, Shaffer A, McBain IT, McGuire PJ, Pittaluga S, Germain RN,
747 Apps R, Schwartz DM, Sadtler K, Moir S, Chertow DS, Kleinstein SH, Khurana S, Tsang JS,
748 Mudd P, Schwartzberg PL, Manthiram K. Adaptive immune responses to SARS-CoV-2 persist
749 in the pharyngeal lymphoid tissue of children. *Nat Immunol* 2023; 24: 186-199.
- 750 44. Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rossler A, Kimpel J, Adolph TE, Tilg H. Postacute
751 COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases.
752 *Gastroenterol* 2022; 163: 495-506 e498.
- 753 45. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J,
754 Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins M, Baden LR, Chan
755 BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson AH,
756 Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZ.
757 Persistence and evolution of SARS-CoV-2 in an immunocompromised host. *NEJM* 2020; 383:
758 2291-2293.
- 759 46. Griffin I, Woodworth KR, Galang RR, Burkel VK, Neelam V, Siebman S, Barton J, Manning SE,
760 Aveni K, Longcore ND, Harvey EM, Ngo V, Mbotha D, Chicchelly S, Lush M, Eckert V,
761 Dzimira P, Sokale A, Valencia-Prado M, Azziz-Baumgartner E, MacNeil A, Gilboa SM, Tong
762 VT. Recurrent SARS-CoV-2 RNA detection after COVID-19 illness onset during pregnancy.
763 *Emerg Infect Dis* 2022; 28: 873-876.
- 764 47. Rodriguez-Grande C, Alcalá L, Estevez A, Sola-Campoy PJ, Buenestado-Serrano S, Martinez-
765 Laperche C, Manuel de la Cueva V, Alonso R, Andres-Zayas C, Adan-Jimenez J, Losada C,
766 Rico-Luna C, Comas I, Gonzalez-Candelas F, Catalan P, Munoz P, Perez-Lago L, Garcia de
767 Viedma D, Gregorio Marañon Microbiology IDCSG. Systematic genomic and clinical analysis
768 of severe acute respiratory syndrome coronavirus 2 reinfections and recurrences involving the
769 same strain. *Emerg Infect Dis* 2022; 28: 85-94.
- 770 48. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in
771 diagnostic samples are not an indicator of active replication. *Nat Commun* 2020; 11: 6059.
- 772 49. Hwang HS, Lo CM, Murphy M, Grudda T, Gallagher N, Luo CH, Robinson ML, Mirza A, Conte
773 M, Conte A, Zhou R, Vergara C, Brooke CB, Pekosz A, Mostafa HH, Manabe YC, Thio CL,
774 Balagopal A. Characterizing SARS-CoV-2 transcription of subgenomic and genomic RNAs
775 during early human infection using multiplexed droplet digital polymerase chain reaction. *J*
776 *Infect Dis* 2023; 227: 981-992.
- 777 50. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with
778 COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
779 *Lancet* 2022; 399: 1941-1953.
- 780 51. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY,
781 Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L,
782 Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD,
783 Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB,
784 Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M,
785 Osinusi A, Nayak S, Lane HC, Members A-SG. Remdesivir for the treatment of Covid-19 -
786 final report. *NEJM* 2020; 383: 1813-1826.
- 787 52. Lapadula G, Bernasconi DP, Bellani G, Soria A, Rona R, Bombino M, Avalli L, Rondelli E,
788 Cortinovis B, Colombo E, Valsecchi MG, Migliorino GM, Bonfanti P, Foti G, Remdesivir-Ria

- 789 Study G. Remdesivir use in patients requiring mechanical ventilation due to COVID-19. *Open*
790 *Forum Infect Dis* 2020; 7: ofaa481.
- 791 53. Pasquini Z, Montalti R, Temperoni C, Canovari B, Mancini M, Tempesta M, Pimpini D, Zallocco
792 N, Barchiesi F. Effectiveness of remdesivir in patients with COVID-19 under mechanical
793 ventilation in an Italian ICU. *J Antimicrob Chemother* 20; 75: 3359-3365.
- 794 54. Budhraj A, Basu A, Gheware A, Abhilash D, Rajagopala S, Pakala S, Sumit M, Ray A,
795 Subramaniam A, Mathur P, Nambirajan A, Kumar S, Gupta R, Wig N, Trikha A, Guleria R,
796 Sarkar C, Gupta I, Jain D. Molecular signature of postmortem lung tissue from COVID-19
797 patients suggests distinct trajectories driving mortality. *Dis Model Mech* 2022; 15.
- 798 55. Melms JC, Biermann J, Huang H, Wang Y, Nair A, Tagore S, Katsyv I, Rendeiro AF, Amin AD,
799 Schapiro D, Frangieh CJ, Luoma AM, Filliol A, Fang Y, Ravichandran H, Clausi MG, Alba
800 GA, Rogava M, Chen SW, Ho P, Montoro DT, Kornberg AE, Han AS, Bakhoun MF,
801 Anandasabapathy N, Suarez-Farinas M, Bakhoun SF, Bram Y, Borczuk A, Guo XV,
802 Lefkowitz JH, Marboe C, Lagana SM, Del Portillo A, Tsai EJ, Zorn E, Markowitz GS,
803 Schwabe RF, Schwartz RE, Elemento O, Saqi A, Hibshoosh H, Que J, Izar B. A molecular
804 single-cell lung atlas of lethal COVID-19. *Nature* 2021; 595: 114-119.
- 805 56. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity,
806 inflammation and intervention. *Mat Rev Immunol* 2020; 20: 363-374.
- 807 57. van de Veerndonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, Engel
808 JJ, Wiersinga WJ, Vlaar APJ, Shankar-Hari M, van der Poll T, Bonten M, Angus DC, van der
809 Meer JWM, Netea MG. A guide to immunotherapy for COVID-19. *Nat Med* 2022; 28: 39-50.
- 810 58. Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, Coppi
811 A, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Zheng NS, Fischer S, Campbell M, Fournier
812 JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE, Yale IT, Dela
813 Cruz C, Farhadian SF, Schulz WL, Ma S, Grubaugh ND, Ko AI, Iwasaki A, Ring AM. Diverse
814 functional autoantibodies in patients with COVID-19. *Nature* 2021; 595: 283-288.
- 815 59. Wang S, Yao X, Ma S, Ping Y, Fan Y, Sun S, He Z, Shi Y, Sun L, Xiao S, Song M, Cai J, Li J, Tang
816 R, Zhao L, Wang C, Wang Q, Zhao L, Hu H, Liu X, Sun G, Chen L, Pan G, Chen H, Li Q,
817 Zhang P, Xu Y, Feng H, Zhao GG, Wen T, Yang Y, Huang X, Li W, Liu Z, Wang H, Wu H,
818 Hu B, Ren Y, Zhou Q, Qu J, Zhang W, Liu GH, Bian XW. A single-cell transcriptomic
819 landscape of the lungs of patients with COVID-19. *Nat Cell Biol* 2021; 23: 1314-1328.
- 820 60. Deinhardt-Emmer S, Wittschieber D, Sanft J, Kleemann S, Elschner S, Haupt KF, Vau V, Haring
821 C, Rodel J, Henke A, Ehrhardt C, Bauer M, Philipp M, Gassler N, Nietzsche S, Löffler B, Mall
822 G. Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the
823 correlation with tissue damage. *Elife* 2021; 10.


824

A**B**


*The 16 decedents that were nasopharyngeal culture-positive were not the same patients that were lung culture-positive. #Immunohistochemistry, RNAseq, electron microscopy and viral culture of other organs was only performed on the Delta cohort.

A


Lung SARS-CoV-2 culture status

**B**

Proportion culture-positive in the upper respiratory tract of ambulatory controls and decedents


**C**

Proportion SARS-CoV-2 PCR positive in the lung versus other organs




Culture-positivity was defined as at least a 3-fold exponential increase in viral load over time.


A




B




C




D





E



F



G



A


Proportion of CD3+ T-cells and CD8+ T-cells infiltrating into the alveoli and interstitial space in culture-negative and culture-positive individuals in the Delta group

medRxiv preprint doi: <https://doi.org/10.1101/2023.03.06.23286882>; this version posted March 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

Frequency of infiltration into the alveoli	Lung culture status		p value
	-ve (n=11#)	+ve (n=7*)	
CD3+			
Medium	55% (6/11)	0% (0/7)	0.038
High	0% (0/11)	0% (0/7)	N/A
CD8+			
Medium	54.5% (6/11)	0% (0/7)	0.038
High	0% (0/11)	0% (0/6)	N/A

B

Representative images showing CD3+ and CD8+ T-cells infiltration into the alveoli and interstitial space of the lung in culture-negative compared to culture-positive individuals in the Delta decedents




C

Key histopathological findings in the of the culture-negative and culture-positive individuals in the Delta group

Lung histology	Lung culture status		p-value
	-ve (n=20*)	+ve (n=13*)	
Alveolar hyaline membranes	16/20 (80%)	8/13 (61.5%)	0.425
Microvascular thrombosis	6/20 (30%)	5/13 (38.5%)	0.714
Organising hyaline membranes	9/12 (75%)	6/7 (86%)	1
Type II pneumocytes proliferation	20/20 (100%)	10/13 (77%)	0.052
Organising pneumonia	6/20 (30%)	4/13 (31%)	1
Lung haemophagocytosis	14/20 (70%)	3/13 (23%)	0.013

D


Both culture-positive and culture-negative decedents present with histopathological findings typically associated with SARS-CoV-2 pneumonia




#IHC was not performed on 5 culture-negative samples. *IHC was not performed on 1 culture-positive sample. *#Histology was not performed on all the biopsy samples. N/A = not applicable .

Enrichment of inflammatory, innate immune and enhanced SARS-CoV-2 entry pathways in the culture-positive versus culture-negative group


A



B



Association of the innate immune response, response to virus, response to cytokine, inflammatory pathways and genes upregulated in the culture-positive group compared to the culture-negative group



ONLINE DATA SUPPLEMENT

SARS-CoV-2 viral replication persists in the human lung for several weeks after symptom onset

Tomasicchio M^{1,2}, Jaumdally S^{1,2}, Wilson L^{1,2}, Kotze A^{1,2}, Semple L^{1,2}, Meier S^{1,2}, Pooran A^{1,2}, Esmail A^{1,2}, Pillay K⁵, Roberts R⁵, Kriel R⁵, Meldau R^{1,2}, Oelofse S^{1,2}, Mandviwala C^{1,2}, Burns J^{1,2}, Londt R^{1,2}, Davids M^{1,2}, van der Merwe^{1,2} C, Roomaney A^{1,2}, Kühn L^{1,2}, Perumal T^{1,2}, Scott A.J^{1,2}, Hale M.J⁶, Baillie V⁷, Mahtab S⁷, Williamson C⁸, Joseph R⁸, Sigal A⁹, Joubert I¹⁰, Piercy J¹⁰, Thomson D¹⁰, Fredericks DL¹⁰, Miller MGA¹⁰, Nunes M.C⁷, Madhi S.A⁷, Dheda K^{1,2,3,4}.

¹ Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine, University of Cape Town and UCT Lung Institute, Cape Town, South Africa.

² South African MRC Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa.

³ Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

⁴ Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, UK.

⁵ Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape Town, South Africa

⁶ Division of Anatomical Pathology, Faculty of Health Sciences, University of the Witwatersrand.

⁷ South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg,

South Africa; Department of Science and Technology/National Research Foundation South African Research Chair Initiative in Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

⁸ Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

⁹ Africa Health Research Institute, Durban, South Africa.

¹⁰ Division of Critical Care, Department of Anaesthesia and Perioperative Medicine, University of Cape Town, South Africa

Correspondence: Keertan Dheda, Centre for Lung Infection and Immunity, Division of Pulmonology and UCT Lung Institute, Dept of Medicine, University of Cape Town, South Africa. E-mail: keertan.dheda@uct.ac.za

Methods.

Viral culture.

The cell line was maintained in Roswell Parks Memorial medium (RPMI) containing 10% foetal bovine serum, 100 IU penicillin/streptomycin, 2 mM L-glutamine, 25 mM HEPES, 1× non-essential amino acids and 0.1 mg/mL sodium pyruvate (ThermoFisher, South Africa; Figure S1). The nasopharyngeal swabs in universal transport medium (UTM) were initially filtered through a 0.22µm filter prior to inoculation. The lung biopsy samples were placed in the well containing the cellular monolayer. The inoculated cultures were grown in a humidified 37°C incubator with 5% CO₂ and cytopathic effect (CPE) and viral replication were monitored on days 1, 3, 6 and 9 by PCR. Viral culture positivity was defined as at least a 3-fold increase in viral load over time. Viral culture reproducibility was performed by a single observer with a total of 6 different viral culture experiments. Each viral culture was performed over a 6-day period with 3 sampling time points (days 1, 3 and 6) and the experiments were all plotted over the assay timepoints to enable line fitment between the data points. A R² value of 0.94 (p=0.017) was obtained (1 being a perfect value), which indicated that the assay was highly reproducible.

Immunohistochemistry.

Sections between 3-4µm thick were placed on adhesive slides and fixed at 37°C overnight. Heat induced epitope retrieval (HIER) time was set to 60 minutes to prevent tissue wash off and possible background staining. The antibodies (anti-CD3 [2GV6], anti-CD4 [SP35], anti-CD8 [SP57] and anti-CD68 [KP-1]; Roche USA) were incubated with the tissue sections for 30 minutes. After antibody and counter staining, slides were visualised using an Olympus BX41 microscope at 40x magnification.

SARS-CoV-2 whole genome sequencing.

Total SARS-CoV-2 RNA was extracted from lung biopsy samples using the Chemagic™ 360 automated system (PerkinElmer, Inc, Waltham, MA) according to the chemagic Viral300 360 H96 drying prefilling VD200309.che protocol. Whole genome amplification and library preparation were performed using the Illumina COVIDSeq Test kit and protocol 1000000128490 v02 (Illumina, Inc., San Diego, CA), and executed on the Hamilton Next Generation StarLet (Hamilton Company). Whole genome amplification was achieved via multiplex polymerase chain reaction performed with the ARTIC V4.1 primers designed to generate 400-bp amplicons with an overlap of 70 bp that spans the 30 kb genome of SARS-CoV-2. Indexed paired-end libraries were normalized to 4 nM concentration, pooled, and denatured with 0.2 N sodium acetate. A 4pM pooled library was spiked with 1% PhiX Control v.3 adaptor-ligated library (Illumina, Inc., San Diego, CA) and sequenced using the MiSeq® Reagent Kit v2 (500 cycle) and sequenced on the MiSeq instrument (Illumina, Inc., San Diego, CA). The quality of sequencing reads was assessed using different tools including FastQC, Fastp, Fastv, Fastq_screen, and Fastx_toolkit. The resulting reads were analysed on Exatype (<https://exatype.com/>) for referenced-based genome assembly to identify minor and major variants. The assembled consensus sequences were analyzed using Nextclade Web (<https://clades.nextstrain.org>) for further quality control and clade assignment.

RNAseq.

RNAseq was performed on lung post-mortem biopsy samples from 24 individuals which included 8 that were COVID culture-positive and 16 that were culture-negative.

Total RNA was extracted from lung biopsy samples using the RNeasy mini plus kit (Qiagen). Ribosomal depletion was performed, and libraries were prepared using the MGIEasy RNA Library Prep Set (Cat. No.: 1000006383, 1000006384, MGI, Shenzhen, China) as per

manufacturer's instructions. Sequencing was performed at the South African Medical Research Council Genomics Centre using DNA nanoball-based technology on the DNBSEQ-G400 (BGI, Shenzhen China) instrument generating 100 bp unstranded paired-end reads. The FastQC program [version 0.11.9; (1)], was used to assess read quality. The Spliced Transcripts Alignment to a Reference (STAR) software [version STAR_2.7.7a; (2)] was used to map reads consecutively to the Ensembl (3) human genome primary assembly (version GRCh38.109) and the SARS CoV-2 reference (ASM985889v3) with the quantMode and GeneCounts option selected to generate raw genewise read counts for each sample. A number of samples failed to pass QC due to a low number of mapped reads (< 2 million). A total of six culture-positive and five culture-negative samples were used in subsequent analysis.

The differential expression (DE) analysis was performed with the edgeR [version 3.38.4; (4)] Bioconductor (5) package. Briefly, raw counts were filtered to remove genes with low expression, normalized, and negative binomial generalized linear models were fitted. The likelihood ratio test was used to identify DE genes when comparing culture-positive to culture-negative samples.

A gene set enrichment analysis (GSEA) for Gene Ontology (Biological Process) was performed on the DE results ranked by fold change using the gseGO function, from the R clusterProfiler (ver: .4.4.4, PMID: 34557778) package.




Figure S1. *In vitro* culture of SARS-CoV-2. (A) Light microscope images showing SARS-CoV-2 viral-induced cytopathic effects (red arrow). (B) Confocal microscopy showing SARS-CoV-2 (red) infecting the cell line. DAPI (blue) was used as the nuclear stain. (C) The limit of detection (LOD) for the PCR assay to detect replicating competent SARS-CoV-2. SARS-CoV-2 viral stock was diluted in 10-fold dilutions from 1×10^5 to 1 copy/ml and co-cultured with confluent H1299 ACE2 cells in a 24-well plate for 9 days. Aliquots were analysed by PCR for viral load on days 1, 3, 6 and 9. The relative viral load (copies/ml) are shown. The dotted line represents the LOD for viral load (1×10^1 copies/ml).

Supplementary results.

Table S1. Demographic and clinical characteristics of the decedents.

	All Patients n=42	Lung biopsy culture-positive n=16	Lung biopsy culture- negative n=26	Univariate #p-value	Multivariate #p-value
Gender				0.758	0.758
Male	47.6% (20/42)	43.8% (7/16)	50% (13/26)		
Female	52.3% (22/42)	56.3% (9/16)	50% (13/26)		
Median age in years (range)	53 (41-62)	58.5 (45.5-64)	49.5 (41-60)	0.2	-
Admission to ICU					
§BMI status					
Underweight	37.5% (9/24)	25% (2/8)	43.8% (7/16)	0.657	
Normal	25% (6/24)	25% (2/8)	25% (4/16)	-	
Overweight	25% (6/24)	25% (2/8)	18.8% (3/16)	-	
Obese	4% (1/24)	12.5% (1/8)	5% (1/16)	-	
Morbidly obese	12.5% (3/24)	12.5% (1/8)	6% (1/16)	-	
Unknown	83.3% (20/24)	62.5% (5/8)	93.8% (15/16)	0.091	
*Co- morbidities					
COPD/Chronic	16.6%	12.5% (1/8)	18.8% (3/16)	-	0.536

bronchitis	(4/24)				
Obesity	41.7% (10/24)	50% (4/8)	37.5% (6/16)	0.415	-
Diabetes	16.6% (4/24)	25% (2/8)	12.5% (2/16)	0.589	0.673
Cancer	33.3% (8/24)	12.5% (1/8)	43.8% (7/16)	0.189	0.578
Hypertension	8.3% (2/24)	12.5% (1/8)	6% (1/16)	-	0.189
^W Other	4% (1/24)	0% (0/8)	6% (1/16)	-	-
HIV-positive	14.3% (6/42)	18.8% (3/16)	11.5% (3/26)	0.658	0.392
^aVaccination status					
Yes	12.5% (3/24)	0% (0/8)	18.8% (3/16)	0.526	
No	87.5% (21/24)	100% (8/8)	81.2% (13/16)	0.526	
Smoker	7.1% (3/42)	12.5% (2/16)	3.8% (1/26)	0.547	
SARS-CoV-2 variant detected in the Beta group by whole genome sequencing					
Beta B.1.1.448	12.5% (1/8)	12.5% (1/8)	-	-	

Beta V2	25% (2/8)	25% (2/8)	-	-	
Unknown ^{***}	83.3% (15/18)	62.5% (5/8)	100% (10/10)	-	
SARS-CoV-2 variant detected in the Delta group by whole genome sequencing					
Alpha V1	4% (1/24)	12.5% (1/8)	0% (0/16)	0.149	
Beta V2	4% (1/24)	0% (0/8)	6.3% (1/16)	0.470	
Delta 21J	29.2% (7/24)	25% (2/8)	31.3% (5/16)	0.751	
Unknown ^{***}	62.5% (15/24)	50% (4/8)	68.8% (11/16)	0.371	
Secondary bacterial infection present (Biofire multiplex PCR)					
Yes	40.5% (17/42)	50% (8/16)	34.6% (9/26)	0.518	0.518
No	57.1% (24/42)	50% (8/16)	61.5% (16/26)	0.518	
Unknown	2.4% (1/42)	0% (0/16)	3.8% (1/26)	-	
Bacterial bronchopneumonia (microbiologically and	11% (4/38)	21% (3/14)	4% (1/24)	0.132	0.443

histopathologically confirmed)					
Steroid usage					
Yes	79.5 % (33/42)	62.5% (10/16)	88.5% (23/26)	0.063	0.063
No	21.4% (9/42)	37.5% (6/16)	11.5% (3/26)	0.063	
Median days of steroid usage (IQR)	8 days (4.5-12) n=24	4.5 days (2.5-6.5) n=8	8 days (4.5-12) n=16	0.015	
COVID-19 status at admission as assessed by nasopharyngeal swab PCR					
PCR positive	90.5% (38/42)	93.8% (15/16)	88.5% (23/26)	-	-
COVID-19 antigen positive (no PCR result)	7.1% (3/42)	6.3% (1/16)	11.5% (3/26)	-	
Unknown	2.4% (1/42)	0% (0/16)	3.8% (1/26)	-	
Median Ct (IQR)	26.1 (21.6-28.3) n=27	26.3 (20.9-28.3) n=11	25.6 (23.4-29.7) n=16	0.429	
Ct value unknown	n=11	n=4	n=7		
COVID-19 status at time of MITS as					

assessed by nasopharyngeal swab PCR					
PCR positive	85.7% (36/42)	100% (16/16)	76.9% (20/26)	0.067	0.003
PCR negative	14.3% (6/42)	0% (0/16)	23.1% (6/26)	0.067	
Median Ct (IQR)	23.5 (20.5-29.9) n=33	23.5 (17.7-25.6) n=15	26.2 (21.4-30.1) n=18	0.166	
Ct value unknown	n=9	n=1	n=8		
Median time from onset of symptoms to death (range)	17 (4-58) n=42	15 (5-27) n=16	18 (4-58) n=26	0.112	0.78
Median days from admission to ICU to death (range)	5 days (1-48) n=42	3 days (1-17) n=16	8 days (0-48) n=26	0.061	0.043
Median days from administration of high flow nasal oxygen to death (range)	11 days (1-24) n=23 ^D	7 days (1-17) n=7	13 days (5-24) n=16	0.053	0.046

[#]p-values are for comparison between lung culture-positive and negative.

[§]BMI status was only recorded for the Delta group.

*Co-morbidities were only recorded for the Delta group. No patients had asthma, current TB, other chronic lung disease, cardiovascular disease, CVA/stroke, malnutrition, organ failure/disease, anaemia, epilepsy, malignancy, on prior steroids or immunosuppressive therapy.

^a Vaccination status was only recorded for the Delta group.

^wPatients with dyslipidemia, ex-smoker, previous lateral medullary syndrome, previous alcohol use, and history of ischemic heart disease.

^gCt value at day of MITS sampling missing for 9 patients.

^hEither the viral load was too low, or the sample was not available.

^D Only recorded for the Delta group.




Figure S2. *In vitro* viral culture of lung biopsies from MV decedents. Description of a new SARS-CoV-2 human biophenotype that has ongoing viral replication in lung for up to 27 days post symptom onset. The lung cancer cell line, H1299 ACE2, was used to culture SARS-CoV-2. The lung biopsy samples were removed and placed in the well containing the cellular monolayer. The inoculated cultures were grown in a humidified 37°C incubator and viral replication were monitored on days 1, 3, 6 and 9 by PCR. DSOTD=days symptom onset to death.




Figure S3. Previously ventilated decedents had active replicating virus in the URT for up to 27 days post symptom onset to death. (A) The lung cancer cell line, H1299 ACE2, was used to culture SARS-CoV-2. The nasopharyngeal swabs in universal transport medium were initially filtered through a 0.22 μ m filter prior to inoculation. The inoculated cultures were grown in a humidified 37°C incubator with 5% CO₂ and cytopathic effect (CPE) and viral replication were monitored on days 1, 3, 6 and 9 by PCR. The days from symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups are shown. The dotted lines represent the median days from symptom onset to death for the lung culture-positive (13 days) and lung culture-negative (18 days) decedents. The days from symptom onset to death for the culture-negative (-ve; green) and culture-positive (+ve; red) groups are shown for the Beta (B) and Delta (C) cohorts. The median days from symptom onset to death for the culture-positive (7 days for the Beta cohort and 16.5 days for the Delta cohort) and culture-negative (10.5 days for the Beta cohort and 23.5 days for the Delta cohort) participants are shown.




Figure S4. Electron micrographs of key clinical features of lung abnormalities associated with acute COVID-19 disease.

The size of the representative scale bars are shown.

Table S2. Histopathological data of the combined study cohort.

Histology Tissue	All patients n=33*	culture- positive patients n=13	culture- negative patients n=20	p-value
LUNG				
Alveolar hyaline membranes	24/33 (73%)	8/13 (61.5%)	16/20 (80%)	0.425
Interstitial oedema	7/19 (37%)	3/7 (43%)	4/12 (33%)	-
Collapsed alveoli	9/33 (27%)	3/13 (23%)	6/20 (30%)	-
Pneumocyte denudation/necrosis	24/33 (73%)	9/13 (69.2%)	15/20 (75%)	-
Endothelial necrosis	5/19 (26%)	3/7 (43%)	2/12 (17%)	0.305
Vascular neutrophil aggregate	6/19 (32%)	3/7 (43%)	3/12 (25%)	0.617
Micro-thromboembolic	11/33 (33%)	5/13 (38.5%)	6/20 (30%)	0.714
Pulmonary haemorrhage	14/33 (42%)	3/13 (23%)	11/20 (55%)	0.087
Pulmonary endothelialitis	5/19 (26%)	2/7 (29%)	3/12 (25%)	-
Organising hyaline membranes	15/19 (79%)	6/7 (86%)	9/12 (75%)	-

Fibroblasts/myofibroblasts proliferation	16/19 (84%)	6/7 (86%)	10/12 (83%)	-
Lymphocytic infiltration	26/33 (79%)	9/13 (69.2%)	17/20 (85%)	0.393
Plasma cell infiltration	4/19 (21%)	1/7 (14%)	3/12 (25%)	-
Type II pneumocytes proliferation	30/33 (91%)	10/13 (77%)	20/20 (100%)	0.052
Atypical pneumocytes	18/19 (95%)	7/7 (100%)	11/12 (92%)	-
Atypical pneumocyte cytomegaly	25/33 (76%)	9/13 (69%)	16/20 (80%)	0.681
Atypical pneumocyte nucleomegaly	21/33 (64%)	7/13 (54%)	14/20 (70%)	0.465
Atypical pneumocyte multinucleation	19/33 (58%)	6/13 (46%)	13/20 (65%)	0.472
Atypical pneumocyte syncytia	5/33 (15%)	3/13 (23%)	2/20 (10%)	0.360
Foamy pneumocytes	19/19 (100%)	7/7 (100%)	12/12 (100%)	-
Arterial/arteriole thrombosis	0/19 (0%)	0/7 (0%)	0/12 (0%)	-
Diffuse collagenous fibrosis	0/19 (0%)	0/7 (0%)	0/12 (0%)	-
Subpleural/interstitial fibrosis	7/19 (37%)	2/7 (29%)	5/12 (42%)	0.657
Honeycomb	5/33 (15%)	2/13 (15.4%)	4/20 (20%)	-
Traction bronchiectasis	0/19 (0%)	0/7 (0%)	0/12 (0%)	-

Squamous met	1/19 (5%)	1/7 (14%)	0/12 (0%)	0.368
Intimal fibrosis	0/19 (0%)	0/7 (0%)	0/12 (0%)	-
Medial hypertrophy	0/19 (0%)	0/7 (0%)	0/12 (0%)	-
Organising pneumonia	10/33 (30%)	4/13 (31%)	6/20 (30%)	-
Bronchopneumonia (neutrophilic infiltrate into the alveoli)	10/33 (30%)	5/13 (38.5%)	5/20 (25%)	0.461
Intranuclear inclusions	0/33 (0%)	0/13 (0%)	0/20 (0%)	-
Intracytoplasmic inclusions	0/33 (0%)	0/13 (0%)	0/20 (0%)	-
Megakaryocytes	22/33 (68%)	8/13 (71%)	14/20 (70%)	0.714
Lung haemophagocytosis (increased alveolar macrophages)	17/33 (52%)	3/13 (23%)	14/20 (70%)	0.013
Lung siderophages	6/33 (18%)	2/13 (15.4%)	4/20 (20%)	-
Necrotising granulomas	1/33 (3%)	1/13 (0%)	0/20 (7.7%)	0.625
Non-necrotising granulomas	0/33 (0%)	0/13(0%)	0/20 (0%)	-
HEART				
Isolated myocyte necrosis	6/33 (18%)	1/13 (14%)	5/20 (25%)	0.364
Cardiac ischaemia	8/17 (47%)	3/7 (43%)	5/10 (50%)	-

Cardiac thrombi	1/33 (3%)	0/13 (0%)	1/20 (5%)	-
Card capillary neutrophil margination	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
RBC fragment	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Lipofuscin	17/17 (100%)	7/7 (100%)	10/10 (100%)	-
Enlarged nuclei	23/33 (70%)	10/13 (77%)	13/20 (65%)	0.467
Cardiac interstitial fibrosis	20/33 (61%)	4/13 (31%)	16/20 (80%)	0.001
Heart endothelialitis	1/33 (3%)	0/13 (0%)	1/20 (10%)	-
Cardiac neutrophils	0/33 (0%)	0/13 (0%)	0/20 (0%)	-
Cardiac lymphocytes	5/33 (15%)	1/13 (7.7%)	4/20 (20%)	0.625
Cardiac histiocytes	2/33 (6%)	1/13 (7.7%)	1/20 (5%)	-
Cardiac eosinophils	1/33 (3%)	0/13 (0%)	1/20 (5%)	-
Cardiac interstitial oedema	4/33 (12%)	0/13 (0%)	4/20 (20%)	0.136
LIVER				
Increase Kupffer	16/17 (94%)	7/7 (100%)	9/10 (90%)	-

Foamy Kupffer	4/17 (24%)	1/7 (14%)	3/10 (30%)	0.603
Liver haemophagocytosis	9/33 (27%)	4/13 (31%)	5/20 (25%)	-
Liver siderophages	1/33 (3%)	0/13 (0%)	1/20 (5%)	-
Liver necrosis	7/17 (41%)	3/7 (43%)	4/10 (40%)	-
Spotty necrosis zone 1	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Spotty necrosis zone 2	2/16 (13%)	1/6 (17%)	1/10 (10%)	-
Spotty necrosis zone 3	2/17 (12%)	1/7 (14%)	1/10 (10%)	-
Confluent necrosis zone 1	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Confluent necrosis zone 2	1/17 (6%)	0/7 (0%)	1/10 (10%)	-
Confluent necrosis zone 3	4/17 (24%)	1/7 (14%)	3/10 (30%)	0.603
Micro steatosis	14/17 (82%)	6/7 (86%)	8/10 (80%)	-
Macro steatosis	13/17 (76%)	6/7 (86%)	7/10 (70%)	-
Cholestasis	8/33 (24%)	3/13 (23%)	5/20 (25%)	-
Liver inflammation	9/17 (53%)	3/7 (43%)	6/10 (60%)	0.637
Liver regeneration	16/17 (94%)	7/7 (100%)	9/10 (90%)	-

Liver congestion	9/33 (%)	8/13 (61.5%)	11/20 (55%)	-
Liver viral inclusions	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Liver fibrosis F1	2/17 (12%)	1/7 (14%)	1/10 (10%)	-
Liver fibrosis F2	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Liver fibrosis F3	1/17 (6%)	0/7 (0%)	1/10 (10%)	-
Liver fibrosis F4	1/17 (6%)	0/7 (0%)	1/10 (10%)	-
Primary sclerosing cholangitis	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Primary biliary cholangitis	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
Extramedullary haematopoiesis (EMH)	0/17 (0%)	0/7 (0%)	0/10 (0%)	-
KIDNEY				
Glom capillary dilatation	10/11 (91%)	5/5 (100%)	5/6 (83%)	-
Glom thrombus	4/11 (36%)	0/5 (0%)	4/6 (67%)	0.061
Glom sclerosis	3/11 (27%)	0/5 (0%)	3/6 (50%)	0.182
Increase mesangium	7/11 (64%)	3/5 (60%)	4/6 (67%)	-
Membrane thickening	0/11 (0%)	0/5 (0%)	0/6 (0%)	-
Acute kidney injury	4/11 (36%)	0/5 (0%)	4/6 (67%)	0.061
Tubular casts	6/11 (55%)	2/5 (40%)	4/6 (67%)	0.242
Isometric vacuole	0/11 (0%)	0/5 (0%)	0/6 (0%)	-
Kidney interstitial lymphocytes	1/11 (9%)	1/5 (20%)	0/6 (0%)	-

Kidney interstitial plasma	1/11 (9%)	1/5 (20%)	0/6 (0%)	-
Kidney interstitial fibrosis	2/11 (18%)	0/5 (0%)	2/6 (33%)	0.455
Kidney interstitial haem	0/11 (0%)	0/5 (0%)	0/6 (0%)	-
Kidney arteriosclerosis	4/11 (36%)	1/5 (20%)	3/6 (50%)	0.546
ADIPOSE				
Fat necrosis	10/21 (48%)	6/8 (75%)	4/13 (31%)	0.082
Fat fibrin	0/21 (0%)	0/8 (0%)	0/13 (0%)	-
Fat unremarked	11/21 (52)	2/8 (25%)	9/13 (69%)	0.082

*Histopathology was not performed on all the biopsy samples.

Table S3. Electron microscopy data of the Delta cohort.

Histology Tissue	All patients n=17*	culture- positive patients n=7	culture- negative patients n=10	p-value
LUNG				
Pneumocyte vacuolation	13/17 (76%)	6/7 (86%)	7/10 (70%)	0.603
Endothelial vacuolation	3/17 (18%)	2/7 (29%)	1/10 (10%)	0.537
Endothelial swelling	13/17 (76%)	6/7 (86%)	7/10 (70%)	0.603
Activated capillary monocytes	1/17 (6%)	0/7 (0%)	1/10 (10%)	-
Pneumocyte detachment	15/17 (88%)	7/7 (100%)	8/10 (80%)	0.485
Collagen deposits	11/16 (69%)	5/6 (83%)	6/10 (60%)	0.588
HEART				
Mitochondrial hypoxic changes	12/12 (100%)	6/6 (100%)	6/6 (100%)	-
Myocyte atrophy and wrinkling	11/11 (100%)	6/6 (100%)	5/5 (100%)	-
Lipofuscin	7/11 (64%)	5/6 (83%)	2/5 (40%)	0.242
Swollen endothelial	10/11 (91%)	6/6 (100%)	4/5 (80%)	-

Fragmented red blood cells	4/11 (36%)	4/6 (57%)	0/5 (0%)	0.061
Myofibrillar disruption	5/11 (45%)	4/6 (57%)	1/5 (20%)	0.242
LIVER				
Swollen/hypoxic mitochondria	15/15 (100%)	6/6 (100%)	9/9 (100%)	-
Increased Kupffer	2/15 (13%)	1/6 (17%)	1/9 (11%)	-
Steatosis	7/15 (47%)	2/6 (33%)	5/9 (56%)	0.398
Haemophagocytosis	10/15 (67%)	4/6 (57%)	6/9 (67%)	-
Detached of endothelial cells	7/15 (47%)	3/6 (50%)	4/9 (44%)	-
Lipidized stellate cells	7/15 (47%)	3/6 (50%)	4/9 (44%)	-
EM liver cholestasis	2/14 (14%)	1/6 (17%)	1/8 (13%)	-
ADIPOSE				
Normal mitochondria	3/14 (21%)	0/6 (0%)	3/8 (38%)	0.209
Slightly enlarged mitochondria	5/14 (36%)	4/6 (57%)	1/8 (13%)	0.091
Enlarged mitochondria	6/14 (43%)	2/6 (33%)	4/8 (50%)	0.627
Swollen endothelial cells present	9/11 (82%)	4/4 (100%)	5/7 (71%)	0.491

*EM was only performed on biopsy samples in the Delta cohort.




Figure S5. Gene expression profile in the culture-negative and culture-positive groups cluster into distinct groups. PCA plot (A) and heatmap (B) showing that distinct genes are differentially regulated in the culture-positive and culture-negative groups.

Table S4. Bacteria and antibiotic resistance profile detected from the lung biopsies of the decedents using multiplex PCR (Biofire).

Patient ID	Secondary bacterial infection present	Number of different bacteria species present	Bacterial species present	Bacterial load (copies/ml)	Antibiotic resistance
UCT 001	Yes	2	<i>Staphylococcus aureus</i> <i>Streptococcus pneumoniae</i>	1×10^6 1×10^4	None detected
UCT 002	No	-	-	-	-
UCT 003	No	-	-	-	-
UCT 004	No	-	-	-	-
UCT 005	No	-	-	-	-
UCT 007	No	-	-	-	-
UCT 008	No	-	-	-	-
UCT 009	Yes	1	<i>Staphylococcus aureus</i>	1×10^5	None detected
UCT 010	Yes	2	<i>Staphylococcus aureus</i> <i>Streptococcus agalactiae</i>	1×10^5 1×10^4	None detected

UCT 012	Yes	2	<i>Haemophilus influenzae</i> <i>Staphylococcus aureus</i>	1x10 ⁶ 1x10 ⁶	None detected
UCT 013	No	-	-	-	-
UCT 014	Yes	1	<i>Acinetobacter calcoaceticus</i> - baumannii complex	1x10 ⁵	Carbapenem (NDM)
UCT 016	No	-	-	-	-
UCT 017	No	-	-	-	-
UCT 018	Yes	2	<i>Acinetobacter calcoaceticus</i> - baumannii complex Proteus spp.	1x10 ⁶ 1x10 ⁶	β-lactam (CTX-M) Carbapenem (NDM)
UCT 020	No	-			
UCT 021	No	-	-	-	-
UCT 022	No	-	-	-	-
UCT 023	Yes	1	<i>Staphylococcus aureus</i>	1x10 ⁵	None detected
UCT 024	Unknow n	-	-	-	-
UCT 026	No	-	-	-	-

UCT 027	No	-	-	-	-
UCT 028	No	-	-	-	-
WITS 2305	Yes	1	<i>Streptococcus agalactiae</i>	1x10 ⁶	
WITS 5033	No	-	-	-	-
WITS 5419	Yes	6	<i>Escherichia coli</i> <i>Staphylococcus aureus</i> <i>Streptococcus agalactiae</i> <i>Klebsiella oxytoca</i> <i>Enterobacter cloacae complex</i> <i>Klebsiella pneumoniae group</i>	1x10 ⁷ 1x10 ⁷ 1x10 ⁶ 1x10 ⁵ 1x10 ⁴ 1x10 ⁴	None detected
WITS 5502	Yes	2	<i>Serratia marcescens</i> <i>Klebsiella pneumoniae group</i>	1x10 ⁵ 1x10 ⁴	β-lactam (CTX-M) Carbapenem (OXA-48-like)
WITS 5517	No	-	-	-	-
WITS 5619	Yes	3	<i>Escherichia coli</i> <i>Klebsiella pneumoniae</i> <i>Serratia marcescens</i>	1x10 ⁴ 1x10 ⁴ 1x10 ⁴	β-lactam (CTX-M) Carbapenem (OXA-48-like)
WITS 5650	Yes	7	<i>Enterobacter cloacae complex</i> <i>Klebsiella oxytoca</i> <i>Klebsiella pneumoniae group</i> <i>Streptococcus pneumoniae</i> <i>Escherichia coli</i>	1x10 ⁷ 1x10 ⁷ 1x10 ⁷ 1x10 ⁷ 1x10 ⁶	β-lactam (CTX-M) Carbapenem (NDN) Carbapenem (OXA-48-like)

			<i>Acinetobacter calcoaceticus-</i> <i>baumannii complex</i>	1x10 ⁴	
WITS 6182	No	-	-	-	-
WITS 7659	No	-	-	-	-
WITS 8734	Yes	2	<i>Acinetobacter calcoaceticus-</i> <i>baumannii complex</i> <i>Klebsiella pneumoniae group</i>	1x10 ⁶ 1x10 ⁴	β-lactam (CTX-M) Carbapenem (NDM) Carbapenem (OXA-48-like)
WITS 9156	Yes	2	<i>Escherichia coli</i> <i>Klebsiella pneumoniae</i>	1x10 ⁴ 1x10 ⁴	β lactam (CTX-M)
WITS 12008	No	-	-	-	-
WITS 12010	Yes	2	<i>Klebsiella pneumoniae</i> <i>Pseudomonas aeruginosa</i>	1x10 ⁷ 1x10 ⁴	Carbapenem (OXA-48-like)
WITS 12011	No	-	-	-	-
WITS 12019	Yes	2	<i>Streptococcus pneumoniae</i> <i>Streptococcus agalactiae</i>	1x10 ⁷ 1x10 ⁴	None detected
WITS 12024	No	-	-	-	-
WITS 12068	No	-	-	-	-
WITS 12115	Yes	1	<i>Streptococcus pneumoniae</i>	1x10 ⁴	None detected

Table S5. Whole genome sequencing results of the viral variants from the study cohort. Only 6 culture-negative and 6 culture-positive samples were available for sequencing because either the viral load was too low ($C_t > 30$) or the sample was not available. It was therefore impossible to perform comparative analysis between the 2 groups because of the small sample number. Data was analysed and sequences aligned using the Stanford University Coronavirus Antiviral and Resistance Database (available at: <https://covdb.stanford.edu/>).

Patient ID*	Source of sample	Variant	Lineage	Sub-lineage	Gene	Unique mutations (found in <0.01% of genomes)	Comments	Ref
WITS 1210	Lung culture supernatant	Beta	20B	B.1.1	-	None		
WITS 12068	Lung culture supernatant	Beta	20H	B.1.3.5.1	-	None		
WITS 12115	Lung culture supernatant	Beta	20H	B.1.351	-	None		
UCT 001	NPS	Alpha	20I	B1.1.7	-	None		
UCT 004	NPS	Beta	20H	B1.351				
UCT 028	NPS	Delta	21J	AY6	-	None		
UCT 016	NPS	Delta	21J	AY91				
UCT 008	NPS	Delta	21J	AY32	Papain-like protease (PLpro)	C55C*W E113EAGV E115ED C118C*W		
					Helicase (nsp13)	P593DE R594X		
					mRNA capping	K433KN P443PAST		

					protein (nsp 14)	K469KMRT A471APST		
					Membrane (M)	S211R S212*DEHQ Y S213X		
UCT 012	NPS	Delta	21J	AY32	-	None		
UCT 018	NPS	Delta	21J	B1.617.2	Main protease (PLpro)	A191T	A191T is a reported resistance mutation against 3C-like protease inhibitor, i.e. nirmatrelvir.	(6)
					RdRP	H650N		
					Spike	V16VFIL K77E		
					Nucleocapsid	S255A		
UCT 022	NPS	Delta	21J	AY32	-	Sequence missing		
UCT 024	NPS	Delta	21J	AY6	Main protease (PLpro)	N1454NIST		

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/) .

					Helicase (nsp13)	F587L T588TIR		
					mRNA capping protein (nsp 14)	M72X R485DE H486X H487X		
					Accessory protein (ORF3a)	K21R D22D*EHQY L94LV		

Table S6. Transcriptomic analysis showing the DE genes in the culture-positive cohort relative to the culture-negative cohort. Genes in black text are human specific. Genes in red text are SARS-CoV-2 specific.

ENZ_ID	Abbreviation	Gene name	logFC	logCPM	p value	FDR
43740569	ORF3a	ORF3a protein	8.35	-0.02	3,23E-07	0.005
43740575	N	Nucleocapsid phosphoprotein	5.5	2.14	1,09E-06	0.009
26585	GREM1	Gremlin 1, DAN family BMP antagonist	3.1	5.43	2,85E-06	0.016
100271927	RASA4B	RAS p21 protein activator 4B	-2.6	3.21	4,27E-06	0.018
27111	SDCBP2	Syndecan binding protein 2	1.67	3.38	8,53E-06	0.029
374	AREG	Amphiregulin	2.11	5	1,10E-05	0.031
771	CA12	Carbonic anhydrase 12	2.11	5.34	1,57E-05	0.034
5055	SERPINB2	Serpin family B member 2	4.43	2.5	1,81E-05	0.034
134285	TMEM171	Transmembrane protein 171	2.22	-0.55	1,82E-05	0.034
338328	GPIHBP1	Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1	-2.25	2.63	2,16E-05	0.035
9982	FGFBP1	Fibroblast growth factor binding protein 1	2.65	2.07	2,44E-05	0.035
80320	SP6	Sp6 transcription factor	1.67	1.8	2,53E-05	0.035
1847	DUSP5	Dual specificity phosphatase 5	1.95	5.27	2,87E-05	0.035
2537	IFI6	Interferon alpha inducible protein 6	2.22	6.62	2,95E-05	0.035
57126	CD177	CD177 molecule	4.15	5.53	4,26E-05	0.047
4915	NTRK2	Neurotrophic receptor tyrosine kinase 2	-2.453	4.7	5,63E-05	0.059
43740568	S spike	Surface glycoprotein/spike glycoprotein	5.32	2.06	6,84E-05	0.067
23105	FSTL4	Follistatin like 4	-1.25	0.8	7,35E-05	0.068
6853	SYN1	Synapsin I	1.95	2.28	8,13E-05	0.071
2827	GPR3	G protein-coupled receptor 3	2.07	0.53	9,07E-05	0.076

Table S7A. Pathways upregulated in the culture-positive cohort relative to the culture-negative

cohort.

GO.ID	Pathway	Total number of genes associated with the pathway	Enrichment score	NES	p value	FDR
GO:0045087	Innate immune response	644	0,462041652	2,23077102	3,19E-26	1,95E-22
GO:0009617	Response to bacterium	502	0,436586937	2,063633461	1,46E-16	2,30E-13
GO:0006954	Inflammatory response	666	0,397117204	1,910719799	1,84E-16	2,30E-13
GO:0009615	Response to virus	337	0,482017466	2,192737214	4,76E-16	4,15E-13
GO:0034097	Response to cytokine	784	0,378837973	1,853887449	4,57E-16	4,15E-13
GO:0042742	Defence response to bacterium	187	0,57065003	2,468893487	2,87E-15	1,95E-12
GO:0097529	Myeloid leukocyte migration	197	0,560938069	2,429088511	7,89E-15	4,82E-12
GO:0071345	Cellular response to cytokine stimulus	700	0,379135852	1,832624826	1,29E-14	7,19E-12
GO:0060326	Cell chemotaxis	260	0,505415546	2,244480472	3,87E-14	1,69E-11
GO:0030595	Leukocyte chemotaxis	199	0,543874673	2,355877738	7,37E-14	2,81E-11
GO:1903047	Mitotic cell cycle process	679	0,37365134	1,802308085	9,44E-14	3,39E-11
GO:0042330	Taxis	521	0,406071568	1,918906559	1,71E-13	5,80E-11
GO:0050900	Leukocyte migration	334	0,461740475	2,094951262	1,90E-13	6,01E-11
GO:0006935	Chemotaxis	519	0,406436107	1,934745764	1,97E-13	6,01E-11
GO:0000280	Nuclear division	380	0,433965649	1,999760733	8,85E-13	2,35E-10

GO:0019221	Cytokine-mediated signalling pathway	401	0,424428923	1,972848247	2,15E-12	5,46E-10
GO:0007059	Chromosome segregation	305	0,457222273	2,071558403	2,72E-12	6,65E-10
GO:0051301	Cell division	573	0,383696506	1,825281074	3,41E-12	7,87E-10
GO:2000147	Positive regulation of cell motility	507	0,386349508	1,825320536	7,25E-12	1,53E-09
GO:0002237	Response to molecule of bacterial origin	294	0,453670477	2,036098196	1,01E-11	2,05E-09

Table S7B. Other pathways of interest upregulated in the culture-positive cohort relative to the culture-negative cohort.

GO.ID	Pathway	Total number of genes associated with the pathway	Enrichment score	NES	FDR
GO:04657	IL-17 signalling pathway	81	0,635892	2.380892	1,53E-07
GO:0002456	T-cell-mediated immunity	96	0,478752825	1,850434828	1,1E-03
GO:0002825	Regulation of T-helper 1 type immune response	25	0,576145234	1,920646442	1,2E-3
GO:0035710	CD4-positive, alpha-beta T cell activation	89	0,470392439	1,801972021	2,1E-03
GO:0035743	CD4-positive, alpha-beta T cell cytokine production	15	0,774743052	2,055120611	3E-03
GO:0002726	Positive regulation of T cell cytokine production	24	0,683190625	2,000311209	3,4E-03

GO:0042110	T cell activation	448	0,294698908	1,379497641	3,5E-03
GO:2000514	Regulation of CD4-positive, alpha-beta T cell activation	56	0,519437379	1,853870959	5,8-03
GO:0002711	Positive regulation of T cell mediated immunity	49	0,543959461	1,869533223	6,7E-3
GO:0042088	Th1 immune response	41	0,576145234	1,920646442	6,7E-03
GO:0002709	Regulation of T-cell mediated immunity	76	0,686930834	2,050809398	7,3E-03
GO:0002369	T-cell cytokine production	34	0,610833263	1,94794025	9,1E-3
GO:0002724	Regulation of T cell cytokine production	34	0,610833263	1,94794025	9,1E-03
GO:0050868	Negative regulation of T cell activation	109	0,413862853	1,63976229	1,1E-02

Table S7C. Genes associated with regulatory pathways of were not up- or downregulated in the culture-positive cohort relative to the culture-negative cohort.

ENZ ID	Gene	LogFC	p-value	FDR
5133	PD-1	-0,580384672	0,352556526	0,875617669
64115	VISTA	0,195588418	0,601343382	0,941688131
84868	TIM-3	0,243920799	0,568480759	0,936258857
1493	CTLA-4	0,100226405	0,868488938	0,987403587
940	CD28	-0,515589978	0,192859859	0,773804865
945	CD33	-0,047967186	0,910411079	0,991670954
3559	CD25	-0,703108858	0,154569866	0,728675358
50943	FOXP3	-0,918764993	0,158003877	0,732211968

The culture-positive group, compared to the culture-negative group, are associated with the enrichment of inflammatory, innate immune and enhanced SARS-CoV-2 entry pathways




Figure S6. The culture-positive group expressed higher levels of genes associated with inflammatory, innate immunity and enhanced SARS-CoV-2 cellular entry pathways compared to the culture-negative cohort. Volcano plots showing the pathways (A) and individual genes (B and C) upregulated in the culture-positive versus the culture-negative cohort. Cyto = cytokine signalling, def. resp.virus = defence of respiratory virus, innate = innate immunology, inflame = inflammatory response, vir_ent=viral entry. The red line represents FDR<0.05 and the black dotted represents p<0.05.

Supplementary references.

1. Andrews S. FastQC: A quality control tool for high throughput sequence data. Accessed on: 1st July 2022. Available at: <https://www.bioinformatics.babraham.ac.uk/projects/fastqc>. 2010.
2. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinform* 2013; **29**(1): 15-21.
3. Howe KL, Achuthan P, Allen J, et al. Ensembl 2021. *Nucleic Acids Res* 2021; **49**(D1): D884-D91.
4. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinform* 2010; **26**(1): 139-40.
5. Huber W, Carey VJ, Gentleman R, et al. Orchestrating high-throughput genomic analysis with Bioconductor. *Nat Methods* 2015; **12**(2): 115-21.
6. Noske G D dSSE, de Godoy M O, Dolci I, Fernandes R S, Guido R V C, Sjö P, Oliva G, Godoy A S. Structural basis of nirmatrelvir and ensitrelvir resistance profiles against SARS-CoV-2 main protease naturally occurring polymorphisms. *J Biol Chem* 2023; **299**(3).